Interior energy-activation of photo-reactive species inside a medium or body

ABSTRACT

A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR 2 ) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

CROSS REFERENCE TO RELATED APPLICATIONS

The present continuation application claim benefit of priority under 35U.S.C. §120 from U.S. application Ser. No. 14/206,337, filed Mar. 12,2014, which makes reference to, claims priority to U.S. provisionalapplication No. 61/792,125 filed on Mar. 15, 2013, the entire contentsof each application are incorporated herein by reference. U.S.provisional application No. 61/792,125 is related to provisional Ser.No. 12/401,478 (now U.S. Pat. No. 8,376,013) entitled “PLASMONICASSISTED SYSTEMS AND METHODS FOR INTERIOR ENERGY-ACTIVATION FROM ANEXTERIOR SOURCE, filed Mar. 10, 2009, the entire contents of which areincorporated herein by reference. This application is related to Ser.No. 13/102,277 entitled “ADHESIVE BONDING COMPOSITION AND METHOD OFUSE,” filed May 6, 2011, the entire contents of which are incorporatedherein by reference. This application is related to provisional Ser. No.61/035,559, filed Mar. 11, 2008, entitled “SYSTEMS AND METHODS FORINTERIOR ENERGY-ACTIVATION FROM AN EXTERIOR SOURCE,” the entire contentsof which are hereby incorporated herein by reference. This applicationis related to provisional Ser. No. 61/030,437, filed Feb. 21, 2008,entitled “METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERSUSING PLASMONICS ENHANCED PHOTOSPECTRAL THERAPY (PEPST) ANDEXCITON-PLASMON ENHANCED PHOTOTHERAPY (EPEP),” the entire contents ofwhich are here by incorporated herein by reference. This application isrelated to non-provisional Ser. No. 12/389,946, filed Feb. 20, 2009,entitled“METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERSUSING PLASMONICS ENHANCED PHOTOSPECTRAL THERAPY (PEPST) ANDEXCITON-PLASMON ENHANCED PHOTOTHERAPY (EPEP),” the entire contents ofwhich are here by incorporated herein by reference. This application isrelated to non-provisional Ser. No. 11/935,655, filed Nov. 6, 2007,entitled “METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION RELATEDDISORDERS,” and to provisional Ser. No. 60/910,663, filed Apr. 8, 2007,entitled “METHOD OF TREATING CELL PROLIFERATION DISORDERS,” the contentsof each of which are here by incorporated by reference in theirentireties. This application is related to and claims priority under 35U.S.C. 119(e) to provisional Ser. No. 61/035,559, filed Mar. 11, 2008,entitled “SYSTEMS AND METHODS FOR INTERIOR ENERGY-ACTIVATION FROM ANEXTERIOR SOURCE,” the entire contents of which are hereby incorporatedherein by reference. This application is elated to and claims priorityunder 35 U.S.C. 119(e) to provisional Ser. No. 61/080,140, filed Jul.11, 2008, entitled “PLASMONIC ASSISTED SYSTEMS AND METHODS FOR INTERIORENERGY-ACTIVATION FROM AN EXTERIOR SOURCE,” the entire contents of whichare hereby incorporated herein by reference.

BACKGROUND OF THE INVENTION

Field of Invention

The invention relates to methods and systems for generating in theinterior of a medium or body radiant energy for producing a change inthe properties of a medium or body by exposure to the radiation.

Discussion of the Background

Presently, light (i.e., electromagnetic radiation from the radiofrequency through the visible to the x-ray and gamma ray wavelengthrange) activated processing is used in a number of industrial processesranging from photoresist curing, to on-demand ozone production, tosterilization, to the promotion of polymer cross-linking activation(e.g. in adhesive and surface coating s) and others. Today, lightactivated processing is seen in these areas to have distinct advantagesover more conventional approaches. For example, conventionalsterilization by steam autoclaving or in food processing bypasteurization may unsuitably overheat the medium to be sterilized. Assuch, light activated curable coating s are one of the fastest growingsectors in the coating s industry. In recent years, this technology hasmade in roads in to a number of market segments like fiber optics,optical and pressure-sensitive adhesives, and automotive applicationslike cured topcoats, and curable powder coating s. The driving force ofthis development is mostly the quest for an increase in productivity ofthe coating and curing process, as conventional nonlight activatedadhesive and surface coating s typically require 1) the elimination ofsolvents from the adhesive and surface coating s to produce a cure and2) a time/temperature cure which adds delay and costs to themanufacturing process.

Moreover, the use of solvent based products in adhesive and surfacecoating s applications is becoming increasingly unattractive because ofrising energy costs and stringent regulation of solvent emissions in tothe atmosphere. Optimum energy savings as well as beneficial ecologicalconsideration are both served by radiation curable adhesive and surfacecoating compositions. Radiation curable polymer cross-linking systemshave been developed to eliminate the need for high oven temperatures andto eliminate the need for expensive solvent recovery systems. In thosesystems, light irradiation initiates free-radical cross-linking in thepresence of common photosensitizers.

However, in the adhesive and surface coating applications and in many ofthe other applications listed above, the light-activated processingslimited due to the penetration depth of light in to the processedmedium. For example, in water sterilization, ultraviolet light sourcesare coupled with agitation and stirring mechanisms in order to ensurethat any bacteria in the water medium will be exposed to the UV light.In light-activated adhesive and surface coating processing, the primarylimitation is that the material to be cured must be directly exposed tothe light, both in type (wavelength or spectral distribution) andintensity. In adhesive and surface coating applications, any“shaded”area will require a secondary cure mechanism, increasing cure time overthe non-shaded areas and further delaying cure time due to the existentof a sealed skin through which subsequent curing must proceed (i.e.,referred to as a cocoon effect).

SUMMARY OF THE INVENTION

The invention overcomes the problems and disadvantages of the prior artas described in the various embodiments below.

In one embodiment, there is provided a method for producing a change ina medium or body. The method includes (1) placing in a vicinity of themedium or body at least one energy modulation agent configured to emitradiation in to the medium or body upon interaction with an initiationenergy and (2) applying the initiation energy from an energy source tothe medium or body. The applied initiation energy interacts with theenergy modulation agent to directly or indirectly produce the change inthe medium or body by the emitted radiation. The energy modulation agenthas a normal predominant emission of radiation in a first wavelengthrange (WR1) outside of a second wavelength range (WR2) known to producethe change, but under exposure to the applied initiation energy producesthe change.

In another embodiment, there is provided a method for curing of aradiation-curable medium. The method includes applying an initiationenergy throughout a composition comprising 1) an uncuredradiation-curable medium and 2) at least one energy modulation agent.The initiation energy interacts with the energy modulation agent todirectly or indirectly cure the uncured medium by polymerization ofpolymers in the medium. The method includes curing the radiation-curablemedium by activating a photoinitiator in the radiation-curable medium.The energy modulation agent has a normal predominant emission ofradiation in a first wavelength range (WR1) outside of a secondwavelength range (WR2) known to activate the photoinitiator, but underexposure to the applied initiation energy cures the medium.

In another embodiment, there is provided a system for producing a changein a medium disposed in an artificial container. The system includes amechanism configured to provide to the medium 1) an activatable agentand 2) at least one energy modulation agent, The energy modulation agentis configured to emit light in to the medium upon interaction with aninitiation energy. The system includes an initiation energy sourceconfigured to apply the initiation energy to the medium. The energymodulation agent has a normal predominant emission of radiation in afirst wavelength range (WR1) outside of a second wavelength range (WR2)known to produce the change, but under exposure to the appliedinitiation energy produces the change.

In another embodiment, there is provided a system for curing of aradiation-curable medium. The system includes 1) a mechanism configuredto supply an uncured radiation-curable medium including an activatableagent and at least one energy modulation agent in to the uncuredradiation-curable medium and 2) an initiation energy source configuredto apply an initiation energy throughout a region including the uncuredradiation-curable medium. The energy modulation agent has a normalpredominant emission of radiation in a first wavelength range (WR1)outside of a second wavelength range (WR2) known to activate thephotoinitiator, but under exposure to the applied initiation energycures the medium.

In another embodiment, there is provided a radiation-curable articleincluding a radiation-curable medium and at least one energy modulationagent distributed throughout the medium. The energy modulation agentbeing a substance which is capable of converting initiation energy to alight capable of curing the radiation-curable medium by polymerizationof polymers in the radiation-curable medium. The energy modulation agenthas a normal predominant emission of radiation in a first wavelengthrange (WR1) outside of a second wavelength range (WR2) known to cure theradiation-curable medium, but under exposure to the applied initiationenergy cures the radiation-curable medium.

In another embodiment, there is provided a method for producing apatterned element inside a structure. The method included (1) placinginside the structure a radiation curable medium including at least oneenergy modulation agent, with the energy modulation agent configured toemit light in to the medium upon interaction with an initiation energy,and (2) applying to the medium the initiation energy from a directed orfocused energy source. The energy modulation agent has a normalpredominant emission of radiation in a first wavelength range (WR1)outside of a second wavelength range (WR2) known to radiation curablemedium, but under exposure to the applied initiation energy cures theradiation curable medium and produces the patterned element inside thestructure.

It is to be understood that both the foregoing general description ofthe invention and the following detailed description are exemplary, butare not restrictive of the invention.

BRIEF DESCRIPTION OF THE FIGURES

A more complete appreciation of the invention and many of the attendantadvantages there of will be readily obtained as the same becomes betterunderstood by reference to the following detailed description whenconsidered in connection with the accompanying drawings, wherein:

FIG. 1 provides an exemplary electromagnetic spectrum in meters (1 nmequals 10⁻⁹ meters);

FIG. 2 is a table providing a list of possible, but not comprehensive,photoactivatable agents;

FIG. 3A is a schematic depicting a system according to one embodiment ofthe invention in which an initiation energy source is directed to aself-contained medium for producing changes in the medium;

FIG. 3B is a schematic depicting x-ray scattering events andinteractions with energy modulation agents in the medium;

FIG. 3C is a depiction of a cascade of reactions where by the initiationenergy interacts with the energy modulation agents and otherconstituents in the medium;

FIG. 4 illustrates an exemplary computer system for implementing variousembodiments of the invention;

FIGS. 5A and 5B are representations of plasmonic nanostructures andtheir theoretical electromagnetic enhancement at different excitationwavelength;

FIGS. 6A-6G provide representative embodiments of plasmonicsphoto-active probes useful in the invention;

FIGS. 7A and 7B are graphical explanations of the plasmonics-enhancedeffect of the invention;

FIGS. 8A-8J show representative embodiments of plasmonics-activenanostructures;

FIG. 9 is a depiction of an x-ray induced optical emission spectra froma red (R) phosphor;

FIG. 10 is a depiction of an x-ray induced optical emission spectra froma green (G) phosphor;

FIG. 11 is a depiction of an x-ray induced optical emission spectra froman orange (O) phosphor;

FIG. 12 is a depiction of an x-ray induced optical emission spectra froma yellow (Y) phosphor;

FIG. 13 is a plot of the levels of relative light output ford-luciferin/luciferase reactions obtained over time for individual typesof phosphors (i.e., no mixtures) exciting a UV-light severable photocagecontaining d-luciferin;

FIG. 14 is a chart comparing peak levels of light output for the ford-luciferin/luciferase reactions from different mixtures (red-green RG,red-yellow RY, green-yellow GY, red-green-yellow RGY exposed to x-rayradiation);

FIG. 15 is plot of a number of different phosphor combinations tested at160 kVp/20 mA anode current/an aluminum filter in the x-ray beam/50 cmspacing conditions for a 1.8 minute x-ray exposure, except of thephosphor group with no exposure to x-ray radiation (the control set);

FIG. 16 is a composite of x-ray induced optical emission spectra ofvarious individual visible emitting phosphors overlaid on each other;

FIG. 17A is a depiction of an x-ray induced optical emission spectrumfrom a red-yellow RY phosphor combination;

FIG. 17B is a depiction of an x-ray induced optical emission spectrumfrom a red-green RG phosphor combination;

FIG. 17C is a depiction of an x-ray induced optical emission spectrumfrom a red-yellow-green RYG phosphor combination;

FIGS. 18A and 18B is a plotted cell kill comparison (shown here as thenumber of surviving colonies) between cancer cells treated with and without Psoralen (AMT) with different phosphor mixtures;

FIGS. 19A and 19B is a plotted cell kill comparison similar to FIGS. 18Aand 18B at higher kVp x-ray conditions;

FIG. 19C is a depiction of the results from a clonogenic colony survivalassay study utilizing a flamingo, yellow, green FYG phosphor combinationin the presence and absence of psoralen (AMT);

FIG. 20 is a representation of an embodiment of a sterilization systemof the invention;

FIG. 21 is a representation of another embodiment of a sterilizationsystem of the invention; and

FIG. 22 is a representation of another embodiment of a sterilizationsystem of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The invention sets forth a novel method for causing a change in activityof an in a medium or body that is effective, specific, and able toproduce a change to the medium or body. The terminology used in thedescription of the invention herein is for the purpose of describingparticular embodiments only and is not intended to be limiting of theinvention. As used in the description of the embodiments of theinvention and the appended claims, the singular forms “a”, “an” and“the” are intended to include the plural forms as well, unless thecontext clearly indicates otherwise. Also, as used herein, “and/or”refers to and encompasses any and all possible combinations of one ormore of the associated listed items. Furthermore, the term “about,” asused herein when referring to a measurable value is meant to encompassvariations of 20%, 10%, 5%, 1%, 0.5%, or even 0.1% of the specifiedamount. It will be further understood that the terms “comprises” and/or“comprising,” when used in this specification, specify the presence ofstated features, integers, steps, operations, elements, and/orcomponents, but do not preclude the presence or addition of one or moreother features, integers, steps, operations, elements, components,and/or groups thereof. Unless otherwise defined, all terms, includingtechnical and scientific terms used in the description, have the samemeaning as commonly understood by one of ordinary skill in the art towhich this invention belongs.

In one embodiment, the present invention provides a method for producinga change in a medium or body, comprising:

-   -   (1) placing in a vicinity of the medium or body at least one        energy modulation agent configured to emit radiation in to the        medium or body upon interaction with an initiation energy; and    -   (2) applying the initiation energy from an energy source to the        medium or body,

wherein the applied initiation energy interacts with the energymodulation agent to directly or indirectly produce the change in themedium or body by said emitted radiation, and

wherein the energy modulation agent has a normal predominant emission ofradiation in a first wavelength range (WR1) outside of a secondwavelength range (WR2) known to produce the change, but under exposureto the applied initiation energy produces the change.

In a preferred embodiment of the present invention the energy modulationagent can be a single energy modulation agent, or a combination or twoor more energy modulation agents. The energy modulation agents of thepresent invention normally convert an incident radiation in to adifferent energy by upconversion or downconversion. Each energymodulation agent typically has a predominant emission wavelength.

In a most preferred embodiment, the present invention methods apply aninitiation energy to these energy modulation agents, which convert theinitiation energy to an emitted radiation at a first wavelength range(WR1), which is indicative of the one or more energy modulation agentsused. Interestingly, the present inventors have found that one can usethese one or more energy modulation agents to initiate reactions, suchas photoreactions, activating photoactivatable agents, curingphotocurable media, etc, even when the reactions being initiated are notnormally initiated by the first wavelength range (WR1), but are rathernormally known to be activated by a second wavelength range (WR2) thatis distinct and different from WR1. This is particularly surprisingsince the energy modulation agents used in this embodiment of thepresent invention are not known to emit radiation at any significantextent, intensity, spectral width, etcat the second wavelength range WR2normally used to activate the reactions of interest.

While the inventors do not wish to be bound to any particular theory orproposed mechanism of action in such cases, it is speculated that thereactions are being activated by a previously unknown pathway, such asthe synergistic combination of the emission spectra of the energymodulation agents to generate a wavelength of radiation not normallyassociated with either energy modulation agent being used, through someform of tunneling effect or photonic coupling (electronic orvibrational) effect to enhance orgenerate radiation at wavelengths notnormally associated with either energy modulation agent, or a pathwaynot yet understood or known.

One possible mechanism involves the chemical interaction of combinationsof phosphor materials in solution and/or under x-ray irradiation. Underx-ray exposure, some of the outer most atomic species of one phosphormight possibly leach in to the media and diffuse through it to reach thesurface(s) of another phosphor in the mixture. In effect, while thepresent invention is not limited to such an effect, phosphors in a givenmixture may ion exchange. In one aspect of this phenomena, the gradientfor ion exchange can be enhanced under x-ray exposure. It is known thatsome phosphors can form solid solutions. It is well known that solidsolutions are formed between Al₂O₃ and Cr₂O₃ where one cation (Al³⁺) inthe host lattice can be substituted by another cation (Cr³⁺). The sizedifference between Cr and Al are known to shift the emission of Ruby(Al₂O₃) from red to green.

The leaching of ionic species out and ion exchange between differentphosphors would predominantly taking place at the outer most atomiclayers with the exchange likely confined to the outer most atomiclayers. For this reason, any new emissions (i.e. emissions which do notnormally belong to either one of the original phosphors) would beexpected to be weak by virtue of the lower number of newly formedemission sites that would be confined to the outer-most atomic layer(the outer surfaces of the particles). Indeed, observations of x-rayinduced fluorescence from the combination of normally visibly emittingphosphors described below show the presence of comparatively weakemissions in the UV spectrum.

In one embodiment of this invention, the following “visible” phosphorscan be used: CaWO₄:Pb²⁺, CaWO₄:W, Sr₃(PO₄)₂: Eu²⁺, Ba₃(PO₄)₂: Eu²⁺,Y₂SiO₅:Ce³⁺, SrMg(SiO₄)₂:Eu²⁺, BaMg₂Al₁₄O₂₄:Eu^(2+,) ZnSiO₄::Mn²⁺,Y₃(Al,Ga)₅O₁₂:Ce³⁺, BaMg₂Al₁₄O₂₄:Mn²⁺, BaMgAl₁₄O₂₃:Mn²⁺,SrAl₁₂SiO₁₉:Mn²⁺, ZnAl₁₂O₁₉: Mn²⁺, CaAl₁₂O₁₉:Mn²⁺, YBO₃:Tb³⁺,Sr₄Si₃O₈Cl₄:Eu³⁺, Y₂O₃:Eu³⁺, Y₂SiO₅:Eu³⁺, Y₃Al₅O₁₂:Eu³⁺, CaSiO₃:Mn²⁺,YVO₄:Eu³⁺, Zn₂SiO₄:Mn²⁺, and combinations thereof.

Regardless of the exact mechanism, the invention provides methods forproducing a change in a medium after generation of radiant energy insidethe medium. In this method, an initiation energy source provides aninitiation energy that penetrates the medium and induces a desiredeffect in the medium byway of interaction of the initiation energy withenergy modulation agents (e.g., phosphors or combination of phosphors)which would not normally be expected to produce the desired effect(e.g., a UV-driven photoreaction).

In one embodiment, the effect produced occurs by photo stimulation of achemical reaction driven by a combination of emitters (e.g., x-raydownconverters or infrared upconverters) where the emitted light fromeach of the individual emitters is nominally lot expected to drive thechemical reaction of interest (e.g., a UV-driven reaction stimulatedprimarily by light emitted in a visible spectrum or a UV-driven reactionstimulated by down-converting phosphors having respective emissions notin the UV range but driving the UV-driven reaction when combined.)

In one embodiment, the initiation energy source is applied directly orindirectly to the medium. Within the context of the invention the phrase“applied indirectly” (or variants of this phrase, such as “applyingindirectly”, “indirectly applies”, “indirectly applied”, “indirectlyapplying”, etc.), when referring to the application of the initiationenergy, means the penetration by the initiation energy in to the mediumbeneath the surface of the medium and to the activatable agents orenergy modulation agents with in a medium. In one embodiment, theinitiation energy interacts with a previously supplied energy modulationagent which then activates the activatable agent.

Although not intending to be bound by any particular theory or beotherwise limited in any way, the following theoretical discussion ofscientific principles and definitions are provided to help the readergain an understanding and appreciation of the invention.

As used herein, an “activatable agent” is an agent that normally existsin an inactive state in the absence of an activation signal. When theagent is activated by an activation signal under activating conditions,the agent is capable of producing a desired pharmacological, cellular,chemical, electrical, or mechanical effect in a medium (i.e. apredetermined change). For example, when photocatalytic agents areirradiated with visible or UV light, these agents induce polymerizationand “curing” of light sensitive adhesives.

Signals that may be used to activate a corresponding agent may include,but are not limited to, photons of specific wavelengths (e.g. x-ray s,or visible light), electromagnetic energy (e.g. radio or microwave),thermal energy, acoustic energy, or any combination thereof. Activationof the agent may be as simple as delivering the signal to the agent ormay further require a set of activation conditions. For example, anactivatable agent, such as a photosensitizer, may be activated by UV-Aradiation (e.g., by UV-A radiation generated internally in the medium).For example, an activatable agent, such as a photosensitizer, may beactivated by UV-B or UV-C radiation. Once activated, the agent in itsactive-state may then directly proceed to produce a predeterminedchange.

Where activation may further require other conditions, mere delivery ofthe activation signal may not be sufficient to bring about thepredetermined change. For example, a photoactive compound that achievesits effect by binding to certain structure in its active state mayrequire physical proximity to the target structure when the activationsignal is delivered. For such activatable agents, delivery of theactivation signal under non-activating conditions will not result in thedesired effect. Some examples of activating conditions may include, butare not limited to, temperature, pH, location, state of the medium, andthe presence or absence of co-factors or conformational changes.

Selection of an activatable agent greatly depends on a number of factorssuch as the desired change, the desired form of activation, as well asthe physical and biochemical constraints that may apply. Exemplaryactivatable agents may include, but are not limited to agents that maybe activated by photonic energy, electromagnetic energy acoustic energy,chemical or enzymatic reactions, thermal energy, microwave energy, orany other suitable activation mechanisms.

When activated, the activatable agent may effect changes that include,but are not limited to an increase in organism activity, a fermentation,a decrease in organism activity, apoptosis, redirection of metabolicpathways, a sterilization of a medium, a cross polymerization and curingof a medium, or a cold pasteurization of a medium.

The mechanisms by which an activatable agent may achieve its desiredeffect are not particularly limited. Such mechanisms may include directaction on a predetermined target as well as indirect actions viaalterations to the biochemical pathways. In one embodiment theactivatable agent is capable of chemically binding/associating to theorganism in a medium. In this embodiment, the activatable agent, isexposed in situ to an activating energy emitted from an energymodulation agent, which, in turn receives energy from an initiationenergy source.

Suitable activatable agents may be a small molecule, a biologicalmolecule such as a protein, or cofactor, a nucleic acid or lipid; asupramolecular assembly; a nanoparticle; or any other molecular entitycapable of producing a predetermined activity once activated.

The activatable agent may be derived from a natural or synthetic origin.Any such molecular entity that may be activated by a suitable activationsignal source to effect a predetermined cellular change may beadvantageously employed in the invention.

Suitable photoactive agents include, but are not limited to: psoralensand psoralen derivatives, pyrenecholesteryloleate, acridine porphyrin,fluorescein, rhodamine, 16-diazorcortisone, ethidium, transition metalcomplexes of bleomycin, transition metal complexes of deglycobleomycin,organoplatinum complexes, alloxazine such as7,8-dimethyl-10-ribitylisoalloxazine (riboflavin),7,8,10-trimethylisoalloxazine (lumiflavin), 7,8-dimethylalloxazine(lumichrome), isoalloxazine-adenine dinucleotide (flavine adeninedinucleotide[FAD]), alloxazine mononucleotide (also known asflavinemononucleotide [FMN] and riboflavine-5-phosphate), vitamin Ks,vitamin L, their metabolites and precursors, and naphthoquinones,naphthalenes, naphthols and their derivatives having planar molecularconformations, porphyrins, dyes such as neutral red, methylene blue,acridine, toluidines, flavine (acriflavine hydrochloride) andphenothiazine derivatives, coumarins, quinolones quinones, andanthroquinones, aluminum (111) phthalocyanine tetrasulfonate,hematoporphyrin and phthalocyanine, and compounds which preferentiallyinteract/adsorb to nucleic acids with little or no effect on proteins.The term “alloxazine” includes isoalloxazines.

Endogenously-based derivatives include synthetically derived analogs andhomologs of endogenous photo activated molecules, which may have or lacklower (1 to 5 carbons) alkyl or halogen substitutes of thephotosensitizers from which they are derived, and which preserve thefunction and substantial non-toxicity. Endogenous molecules areinherently non-toxic and may not yield toxic photoproducts afterphotoradiation.

FIG. 1 provides an exemplary electromagnetic spectrum in meters (1 nmequals 1 nanometer). As used herein, an “energy modulation agent” refersto an agent that is capable of receiving an energy input from a sourceand then re-emitting a different energy to a receiving target. Energytransfer among molecules may occur in a number of ways. The form ofenergy may be electronic, thermal, vibronic, electromagnetic, kinetic,or chemical in nature. Energy may be transferred from one molecule toanother (intermolecular transfer) or from one part of a molecule toanother part of the same molecule (intramolecular transfer). Forexample, a modulation agent may receive electromagnetic energy andre-emit energy in the form of thermal energy or energy which otherwisecontributes to heating the environment invicinity of the light emission.

Table 1 in FIG. 2 provides a list of photoactivatable agents that may beused as primary or secondary internal light sources. For example, thephotoactivatable agents could be receptors of X-ray induced emissionsfrom nanoparticles (to be discussed later) and which in turn emit asecondary light. In some mediums, it may be that the excitationwavelengths in Table 1 are transparent to the particular medium and theemission wavelengths are highly absorbent (due to, for example,molecular or solid state band gap transitions). In those cases, thephotoreactive agents in Table 1 would be the primary sources forinternal light generation.

In various embodiments, the energy modulation agent (down convertersmixtures of down converters, up converters, mixtures of up converters,and combinations thereof) receives energy (from a source and re-emitsthe energy (e.g. UV-A and/or visible light). Some energy modulationagents may have a very short energy retention time (on the order offemtoseconds (fs), e.g. fluorescent molecules) whereas others may have avery long half-life (or the order of minutes to hours, e.g. luminescentor phosphorescent molecules). Suitable energy modulation agents include,but are not limited to, a biocompatible fluorescing metal nanoparticle,fluorescing dye molecule, gold nanoparticle, a quantum dot, a quantumdot encapsulated by polyamidoamine dendrimers, a luciferase, abiocompatible phosphorescent molecule, a combined electromagnetic energyharvester molecule, and a lanthanide chelate capable of intenseluminescence. These energy modulation agents (some of which aredescribed above as nanoparticles) need not be of nanometer size and canin various embodiments of this invention be of micron-sized proportions.Typically, the energy modulation agents (downconverters, mixtures ofdown converters, upconverters, mixtures of up converters, andcombinations thereof) induce photoreactive changes in the medium and arenot used for the purpose of exclusively heating the medium.

Various exemplary uses are described in the embodiments below.

The energy modulation agents may further be coupled to a carrier fortargeting purposes. For example, a biocompatible molecule, such as afluorescing metal nanoparticle or fluorescing dye molecule that emits inthe UV-A band, may be selected as the energy modulation agent. Theenergy modulation agent may be preferably directed to the desired siteby systemic administration in to a medium. For example, a UV-A emittingenergy modulation agent may be distributed in the medium by physicalinsertion and or mixing, or by conjugating the UV-A emitting energymodulation agent with a specific carrier, such as a protein or peptide,lipid, chitin or chitin-derivative, a chelate or other functionalizedcarrier that is capable of concentrating the UV-A emitting source in aspecific target region of the medium.

Additionally, the energy modulation agent can based alone or as a seriesof two or more energy modulation agents such that the energy modulationagents provide an energy cascade. Thus, the first energy modulationagent in the cascade will absorb the activation energy, convert it to adifferent energy which is then absorbed by the second energy modulationin the cascade, and so forth until the end of the cascade is reachedwith the final energy modulation agent in the cascade emitting theenergy necessary to activate the activatable agent. Alternatively, oneor more energy modulation agents in the cascade may also activateadditional activatable agents.

Although the activatable agent and the energy modulation agent can bedistinct and separate, it will be understood that the two agents neednot be independent and separate entities. In fact, the two agents may beassociated with each other via a number of different configurations.Where the two agents are independent and separately movable from eachother, they can generally interact with each other via diffusion,ion-exchange electrostatic attraction and chance encounters with in acommon surrounding medium. Where the activatable agent and the energymodulation agent are not separate, they may be combined in to one singleentity.

The initiation energy source can be any energy source capable ofproviding energy at a level sufficient to activate the activatable agentdirectly, or to provide the energy modulation agent with the inputneeded to emit the activation energy for the activatable agent (indirectactivation). Preferable initiation energy sources include any devicecapable of generating x-ray, y-ray, gamma-ray, or electron beams.

In one embodiment, the initiation energy is capable of penetratingcompletely through the medium. Within the context of the invention, thephrase “capable of penetrating completely through the medium” is used torefer to energy capable of penetrating a container to any distancenecessary to activate the activatable agent with in the medium. It isnot required that the energy applied actually pass completely throughthe medium, merely that it be capable of doing so in order to permitpenetration to any desired distance to activate the activatable agent.The type of energy source chosen will depend on the medium itself.

Photoactivatable agents may be stimulated by an energy source throughmechanisms such as irradiation, resonance energy transfer, excitonmigration, ion-exchange free radicals, electron injection, or chemicalreaction, to an activated energy state that is capable of producing thepredetermined change desired. One advantage is that wavelengths ofemitted radiation may be used to selectively stimulate one or morephotoactivatable agents or energy modulation agents capable ofstimulating the one or more photoactivatable agents. The energymodulation agent suitably stimulated at a wavelength and energy thatcauses little or no change to the medium.

Within the context of the invention, the applying of the initiationenergy source means the application of an agent, that itself producesthe initiation energy, in a manner that permits the agent to arrive atthe target structure with in the medium. The application can take anyform. Further, the initiation energy source in this embodiment can be inany form, including, but not limited to, tablet, powder, liquidsolution, liquid suspension, liquid dispersion, gas or vapor, etc.

In another embodiment, the invention includes the application of theactivatable agent, along with a source of chemical energy such aschemiluminescence, phosphorescence or bioluminescence. The source ofchemical energy can be a chemical reaction between two or morecompounds, or can be induced by activating a chemiluminescent,phosphorescent or bioluminescent compound with an appropriate activationenergy, either outside the medium or inside the medium, with thechemiluminescence, phosphorescence or bioluminescence being allowed toactivate the activatable agent in the medium. The administration of theactivatable agent and the source of chemical energy can be performedsequentially in any order or can be performed simultaneously.

In the case of certain sources of such chemical energy, the applicationof the chemical energy source can be performed after activation outsidethe medium, with the lifetime of the emission of the energy being up toseveral hours for certain types of phosphorescent materials for example.

When molecules absorb excitation light, electrons undergo transitionsfrom the ground state to an excited electronic state. The electronicexcitation energy subsequently relaxes via radiative emission(luminescence) and radiationless decay channels. When a molecule absorbsexcitation energy, it is elevated from S_(o) to some vibrational levelof one of the excited singlet states, S_(n), in the manifold S₁, . . . ,S_(n). In condensed media, the molecules in the S, state deactivaterapidly, with in 10⁻¹³ to 10⁻¹¹ s via vibrational relaxation (VR)processes, ensuring that they are in the lowest vibrational levels ofS_(n) possible. Since the VR process is faster than electronictransitions, any excess vibrational energy is rapidly lost as themolecules are de activated to lower vibronic levels of the correspondingexcited electronic state. This excess VR energy is released as thermalenergy to the surrounding medium. From the S_(n) state, the moleculeactivates rapidly to the isoenergetic vibrational level of a lowerelectronic state such as S_(n-1) via an internal conversion (IC)process. IC processes are transitions between states of the samemultiplicity.

The molecule subsequently deactivates to the lowest vibronic levels ofS_(n-1) via a VR process. By a succession of IC processes immediatelyfollowed by VR processes, the molecule deactivates rapidly to the groundstate S₁. This process results in excess VR and IC energy released asthermal energy to the surrounding medium leading to the overheating ofthe local environment surrounding the light absorbing drug molecules.The heat produced results in local changes in the medium.

Light absorbing species in various embodiments can include naturalchromophores tissue or exogenous dye compounds such as indocyaninegreen, naphthalocyanines, and porphyrins coordinated with transitionmetals and metallic nanoparticles and nanoshells of metals.

Yet another example is that nanoparticles or nanoclusters of certainatoms ma be introduced such that they are capable of resonance energytransfer over comparatively large distances, such as greater than onenanometer, more preferably greater than five nanometers, even morepreferably at least 10 nanometers. Functionally, resonance energytransfer mayhave a large enough “Foerster” distance (R₀), such thatnanoparticles in one part of a medium are capable of stimulatingactivation of photoactivatable agents disposed in a distant portion ofthe medium, so long as the distance does not greatly exceed R₀. Forexample, gold nanospheres having a size of 5 atoms of gold have beenshown to have an emission band in the ultraviolet range, recently.

In an additional embodiment, the photoactivatable agent can be aphotocaged complex having an active agent (which can be an activatableagent) contained with in a photocage. In various embodiments, thephotocage molecule releases the agent in to the medium. The active agentcan be bulked up with other molecules that prevent it from binding tospecific targets, thus masking its activity. When the photocage complexis photo activated, the bulk falls off, exposing the active agent. Insuch a photocage complex, the photocage molecules can be photoactive(i.e. when photo activated, they are caused to dissociate from thephotocage complex thus exposing the active agent with in), or the activeagent can be the photoactivatable agent (which when photo activatedcauses the photocage to fall off), or both the photocage and the activeagent are photo activated, with the same or different wavelengths.

In one embodiment of this invention, medical bottle caps which need tobe sterilized have under the base cap material a glued seal materialwhich contacts the base of the medical bottle. Because steam autoclavesare insufficient for this purpose, one embodiment of the invention usesluminescing particles included in the adhesive layer when the sealmaterial is applied to the bottle cap. Then, X-ray irradiation becomescapable of curing the adhesive and producing with in the adhesive mediumradiation for direct sterilization or the production of singlet oxygenand/or ozone for biological germicide.

The activatable agent and derivatives there of as well as the energymodulation agent, can be incorporated in to compositions suitable fordelivery to particular mediums. The composition can also include atleast one additive having a complementary effect upon the medium, suchas a lubricant or a sealant.

The carrier can be a solvent or dispersion medium containing, forexample, water, ethanol, polyol (for example, glycerol, propyleneglycol,and liquid polyethylene glycol, and the like), and suitable mixturesthereof. The proper fluidity can be maintained, for example, by the useof a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersion and by the use of surfactants.

Referring to FIG. 3A, an exemplary system according to one embodiment ofthe invention may have an initiation energy source 1 directed at medium4. Activatable agents 2 and an energy modulation agents 3 are dispersedthroughout the medium 4. The initiation energy source 1 may additionallybe connected via a network 8 to a computer system 5 capable of directingthe delivery of the initiation energy. In various embodiments, theenergy modulation agents 3 are encapsulated energy modulation agents 6,depicted in FIG. 3 as silica encased energy modulation agents. As shownin FIG. 3A, initiation energy 7 in the form of radiation from theinitiation energy source 1 permeated throughout the medium 4. Theinitiation energy source 1 can be an external energy source or an energysource located at least partially in the medium 4. Activatable agents 2and/or the energy modulation agents 3 can include plasmonics agentswhich enhance either the applied energy or the energy emitted from theenergy modulation agents 3 so as to directly or indirectly produce achange in the medium.

In various embodiments, the initiation energy source 1 may be a linearaccelerator equipped with image guided computer-control capability todeliver a precisely calibrated beam of radiation to a pre-selectedcoordinate. One example of such linear accelerators is the SmartBeam™IMRT (intensity modulated radiation therapy) system from Varian medicalsystems (Varian Medical Systems, Inc., Palo Alto, Calif.). In otherembodiments, the initiation energy source 1 may be commerciallyavailable components of X-ray machines or non-medical X-ray machines.X-ray machines that produce from 10 to 150 keV X-rays are readilyavailable in the marketplace. For instance, the General ElectricDefinium series or the Siemens MULTIX series are but two examples oftypical X-ray machines designed for the medical industry, while theEagle Pack series from Smith Detection is are example of a non-medicalX-ray machine. As such, the invention is capable of performing itsdesired function when used in conjunction with commercial X-rayequipment.

According to another embodiment of the invention, energy modulationelements 6 can be placed in the vicinity of a fluid medium 4 (e.g., aliquid or other fluid-like medium) and held inside a container. Thecontainer can be made of a material that is “transparent” to theradiation. For example, plastic, quartz, glass, or aluminum containerswould be sufficiently transparent to X-rays, while plastic or quartz orglass containers would be transparent to microwave or radio frequencylight. The energy modulation elements 6 can be dispersed uniformlythroughout the medium or may be segregated in distinct parts of themedium or further separated physically from the medium by encapsulationstructures. A supply would provide the medium 4 to the container.

FIG. 3B is a schematic depicting x-ray scattering events andinteractions with energy modulation agents in the medium. In oneembodiment, the effect produced by the interactions of the x-rays andenergy modulation agents with the medium occurs by pathways not yetcertain where internally produced light (IR, visible, and/or UV) aloneor in combination with the x-ray exposure drive a chemical reaction inthe medium or to the energy modulation agents themselves. These pathwaysmay be influenced by the generation of free radicals inside the medium.These pathways may be influenced by the generation of ions inside themedium. These pathways may be influenced by the scattering of x-raysinside the medium. These pathways may be influenced by the generation ofemitted and re-emitted light in inside the medium. These pathways may bea combination of these factors.

Further, these pathways may include the in situ generation of singletoxygen and/or ozone to produce a change in the medium. For example, thephotoactivatable agents may be stimulated through mechanisms such asirradiation, resonance energy transfer, exciton migration, ion-exchange,free radicals, electron injection, or chemical reaction to where“activated” agent is capable of producing the predetermined changedesired.

In another embodiment, clusters of energy modulations agents (orchemically reactive agents or plasmonic agents) may be provided to alocal site where x-ray exposure or internally generated light breaksapart the clusters in to a form more useful to treatment at the localsite or more useful to generating a local change in the medium near bywhere the clusters existed.

FIG. 3C is a depiction of a cascade of reactions where by the initiationenergy interacts with the energy modulation agents and otherconstituents in the medium to produce a number of primary and secondaryreactions. These interactions for example can lead to the production ofelectrons and/or reactive oxygen species (ROS), can sensitize adjacentchemistry, lower energy barriers and promote chemical reactions, candrive chemical reactions, release surface coating s and species, and/orbreak aggregates permitting the dispersion of more energy modulators attarget sites, can promote additional interactions with primary X-Rayenergy, promote additional interactions with scattered X-Ray energy,and/or promote diffusion and on exchange, can provide a potential forcreation of a transitional state and/or provide additional colorcenters, and can be responsible for emissions at new wavelengths of UV,visible infrared, or thermal energy not normally present with out theseinteractions. These interactions can result in increased photonicenergy, can drive photo catalysis, and can provide mechanical energy tothe medium.

As an illustration of a complex interaction process of this invention,in one embodiment, a coating is applied to an energy modulator. Thecoating has at least one embedded (not tethered) biotherapeutic agent.The coating is made of chemical that maintain emissions from the energymodulator (e.g., known visible or UV emissions). The coated energymodulator is delivered to the medium and exposed to x-rays with anintensity that allows the breaking of the coating or the breaking of theouter surfaces of the phosphors (which then release the biotherapeuticagent). Optionally, the x-ray energy and/or intensity can be lowered toactivate photonic emission of the phosphor with out necessarily furthersurface aberration.

In the invention, energy transfer among molecules may occur in a numberof ways. The form of energy may be electronic, thermal, electromagnetic,kinetic, or chemical in nature. The energy can be modulated up to emithigher energy from the energy modulation agent compared to the inputinitiation energy, or can be modulated down to emit lower energy fromthe energy modulation agent compared to the input initiation energy.Energy may be transferred from one molecule to another (intermoleculartransfer) or from one part of a molecule to another part of the samemolecule (intramolecular transfer). For example, a modulation agent mayreceive electromagnetic energy and re-emit the energy in the form of adifferent energy. In various embodiments, the energy modulation agentsreceive higher energy (e.g. x-ray) and re-emits in lower energy (e.g.UV-A, UV-B, UV-C). In other embodiments different energy modulationagents would receive lower energy (e.g., infrared or near-infrared) andemits in a higher energy (e.g., visible or ultraviolet).

Energy transfer processes are also referred to as molecular excitation.Some modulation agents may have a very short energy retention time (onthe order of fs-ns, e.g. fluorescent molecules) whereas others may havea very long half-life (on the order of seconds to hours, e.g.luminescent inorganic molecules or phosphorescent molecules). Suitableenergy modulation agents include, but are not limited to, a metalnanoparticle or a biocompatible metal nanoparticle, a metal coated oruncoated with a biocompatible outer layer, a chemiluminescent moleculewhose rate of luminescence is increased by microwave activation,fluorescing dye molecule, gold nanoparticle, a water soluble quantum dotencapsulated by polyamidoamine dendrimers, a luciferase, a biocompatiblephosphorescent molecule, a biocompatible fluorescent molecule, abiocompatible scattering molecule, a combined electromagnetic energyharvester molecule, and a lanthanide chelate capable of intenseluminescence. As noted above, these energy modulation agents (some ofwhich are described above as nanoparticles) need not be of nanometersize and can in various embodiments of this invention be of micron-sizedproportions. Various exemplary uses of the energy modulation agents ofthis invention are described.

The modulation agents may further be coupled to a carrier for targetingpurposes. For example, a biocompatible molecule, such as a fluorescingmetal nanoparticle or fluorescing dye molecule that emits in the UV-Aband, may be selected as the energy modulation agent.

The energy modulation agent may be preferably directed to the desiredsite (e.g. in close vicinity to a photoactive substance such as forexample a photocatalyst or a photo initiator) by pre-distribution of theenergy modulation agent in to a medium to be exposed to the activationenergy. For example, a UV-A emitting energy modulation agent may beconcentrated in joints for adhesion of two parts together by physicalinsertion or by conjugating the UV-A emitting energy modulation agentwith a photoactivatable resin.

Additionally, the energy modulation agent can based alone or as a seriesof two or more energy modulation agents wherein the energy modulationagents provide an energy cascade. Thus, the first energy modulationagent in the cascade will absorb the activation energy, convert it to adifferent energy which is then absorbed by the second energy modulationin the cascade, and so forth until the end of the cascades reached withthe final energy modulation agent in the cascade emitting the energynecessary to activate the photo-activatable agent in the medium.

Although the photo-activatable agent and the energy modulation agent canbe distinct and separate, it will be understood that the two agents neednot be independent and separate entities. In fact, the two agents may beassociated with each other via a number of different configurations.Where the two agents are independent and separately movable from eachother, they generally interact with each other via diffusion,electrostatic interactions and chance encounters with in a commonsurrounding medium. Where the photo-activatable agent and the energymodulation agent are not separate, they may be combined in to one singleentity.

The initiation energy source can be any energy source capable ofproviding energy at a level sufficient to activate the activatable agentdirectly, or to provide the energy modulation agent with the inputneeded to emit the activation energy for the activatable agent (indirectactivation). Preferable initiation energy sources include, but are notlimited to, UV-A lamps, UV-B lamps, UC-C lamps, or fiber optic lines, alight needle, an endoscope, and a linear accelerator that generatesx-ray, gamma-ray, or electron beams. The energy used can be any type,including but not limited to, gamma ray, x-ray, UV, near-UV, visible,Near IR, IR, microwave, radiowave, etc. In a preferred embodiment, theinitiation energy capable of penetrating completely through the subject.Exemplary initiation energy sources that are capable of penetratingcompletely through the subject include, but are not limited to, x-ray s,gamma rays, electron beams, microwaves and radio waves.

In one embodiment of this invention, plasmonic structures can beutilized. The plasmonics-enhanced principles based in theory onenhancement mechanisms of the electromagnetic field effect.Electromagnetic enhancements are divided in to two main classes a)enhancements that occur only in the presence of a radiation field, andb) enhancements that occur even with out a radiation field. The firstclass of enhancements is further divided in to several processes. Plasmaresonances on substrate surfaces, also called surface plasmons, providea significant contribution to electromagnetic enhancement. One effectivetype of plasmonics-active substrate includes nanostructured metalparticles, protrusions, or rough surfaces of metallic materials.Incident light irradiating these surfaces excites conduction electronsin the metal, and induces the excitation of surface plasmons leading toRaman/luminescence enhancement. Ata plasmon frequency, metalnanoparticles (or other nanostructure roughened structures) becomepolarized, resulting in large field induced polarizations and thus largelocal fields on the surface. These local fields increase theluminescence/Raman emission intensity, which is proportional to thesquare of the applied field at the molecule.

As a result, the effective electromagnetic field experienced by ananalyte molecule on these surfaces is much larger than the actualapplied field. This field decreases as l/r³ away from the surface.Therefore, in the electromagnetic models, the luminescence/Raman-activeanalyte molecule is not required to be in contact with the metallicsurface but can be located anywhere within the range of the enhancedlocal field, which can polarize this molecule. The dipole oscillating atthe wavelength λ of Raman or luminescence can, in turn, polarize themetallic nanostructures and, if λ is in resonance with the localizedsurface plasmons, the nanostructures can enhance the observed emissionlight (Raman or luminescence).

Accordingly, plasmonics-active metal nanoparticles also exhibit stronglyenhanced visible and near-infrared light absorption, several orders ofmagnitude more intense compared to conventional laser photo therapyagents. The use of plasmonic nanoparticles as highly enhancedphotoabsorbing agents thus provides a selective and efficient strategyfor the efficient use of internally generated light.

Accordingly, the invention utilizes several important mechanisms:

-   -   (A) Increased absorption of the excitation light by the        plasmonic metal nanoparticles, resulting in enhanced        photoactivation of photoinitiators orphotocatalysts;    -   (B) Increased absorption of the excitation light by the        plasmonic metal nanoparticles that serve as more efficient        energy modulation agent systems, yielding more light for        increased excitation of the photoinitiators or photocatalysts;    -   (C) Increased absorption of the excitation light by the medium        material on or near the plasmonic metal nanoparticles;    -   (D) Increased light absorption of the energy modulation agent        molecules adsorbed on or near the metal nanoparticles;    -   (E) Amplified light emission from the energy modulation agent        molecules adsorbed on or near the metal nanoparticles; and    -   (F) Increased absorption of emission light emitted from the        energy modulation agent by the photoinitiators orphotocatalysts.

As discussed above, one of several phenomena that can enhance theefficiency of light emitted (Raman or luminescence) from moleculesadsorbed or near a metal nanostructures Raman scatter is thesurface-enhanced Raman scattering (SERS) effect In 1984, the generalapplicability of SERS as an analytical technique was first reported byone of the present inventors, and the possibility of SERS measurementfor a variety of chemicals including several homocyclic and heterocyclicpolyaromatic compounds [T. Vo-Dinh, M. Y. K. Hiromoto, G. M. Begun andR. L. Moody, “Surface-enhanced Raman spectroscopy for trace organicanalysis,” Anal. Chem., vol. 56, 1667, 1984], the entire contents ofwhich are incorporated herein by reference. Extensive research has beendevoted to understanding and modeling the Raman enhancement in SERSsince the mid 1980's. FIG. 5, for example, shows the early work byKerker modeling electromagnetic field enhancements for spherical silvernanoparticles and metallic nanoshells around dielectric cores as farback as 1984 [M. M. Kerker, Acc. Chem. Res., 17, 370 (1984)], the entirecontents of which are incorporated herein by reference This figure showsthe result of theoretical calculations of electromagnetic enhancementsfor isolated spherical nanospheres and nanoshells at differentexcitation wavelengths. The intensity of the normally weak Ramanscattering process is increased by factors as large as 10¹³ or 10¹⁵ forcompounds adsorbed on to a SERS substrate, allowing for single-moleculedetection. As a result of the electromagnetic field enhancementsproduced near nanostructured metal surfaces, nanoparticles have foundincreased use as fluorescence and Raman nanoprobes.

Theoretical models indicate that it is possible to tune the size of thenanoparticles and the nanoshells to the excitation wavelength.Experimental evidence suggests that the origin of the 10⁶- to 10¹⁵-foldRaman enhancement primarily arises from two mechanisms: a) anelectromagnetic “lightning rod” effect occurring near metal surfacestructures associated with large local fields caused by electromagneticresonances, often referred to as “surface plasmons,” and b) an effectassociated with direct energy transfer between the molecule and themetal surface.

According to classical electromagnetic theory, electromagnetic fieldscan be locally amplified when light is incident on metal nanostructures.These field enhancements an be quite large (typically 10⁶- to 10⁷-fold,but up to 10¹⁵-fold enhancement at“hot spots”). When a nanostructuredmetallic surface is irradiated by an electromagnetic field (e.g., alaser beam), electrons with in the conduction band begin to oscillate ata frequency equal to that of the incident light. These oscillatingelectrons, called “surface plasmons,” produce a secondary electric fieldwhich adds to the incident field. If these oscillating electrons arespatially confined, as is the case for isolated metallic nanospheres orroughened metallic surfaces (nanostructures), there is a characteristicfrequency (the plasmon frequency) at which there is a resonant responseof the collective oscillations to the incident field. This conditionyields intense localized field enhancements that can interact withmolecules on or near the metal surface. In an effect analogous to a“lightning rod,” secondary fields are typically most concentrated itpoints of high curvature on the roughened metal surface.

FIGS. 6A-6G shows a number of the various embodiments ofplasmonics-enhanced probe structures (PEPST) that can be designed:

(A) Photo-activatable (PA) molecules bound to a metal (e.g., gold)nanoparticle;

(B) Photo-activatable (PA) molecule covered with metal nanoparticles;

(C) Metal nanoparticle covered with PA nanocap;

(D) PA-containing nanoparticle covered with metal nanocap;

(E) Metal nanoparticle covered with PA nanoshell;

(F) PA-containing nanoparticle covered with metal nanoshell; and

(G) PA-containing nanoparticle covered with metal nanoshell withprotective coating layer.

A basic embodiment is shown in FIG. 6A. This embodiment shows a PAmolecules bound to a metal (e.g., gold) nanoparticle. FIG. 7 illustratesthe plasmonics-enhancement effect as it would be used in this inventionto enhance the interaction of the primary excitation light source withenergy modulation agents or to enhance the interaction of thesecondarily produced light with the medium in effecting a change to themedium. Radiation of suitable energy is used to excite the plasmonicstructures which in turn activates for example near by photoinitiators.

For example, light of a HeNe laser (632.8-nm excitation) can be used forexcitation. In this case the metal nanoparticles are designed to exhibitstrong plasmon resonance band around 632.8 nm. The surface plasmonresonance effect amplifies the excitation light at the nanoparticles,resulting in an increased photoactivation of a photo-initiator or aphoto-catalyst and improved reaction kinetic. Further, for sterilizationapplications, the effect increases the likelihood for a germicide eventin the medium in vicinity of the nanoparticles. While light such as theHeNe laser light might be scattered and absorbed in the medium, thepresence of the PEPST structures enhances the interaction of thepenetrating light beyond that which would normally be considered useful.The plasmonics-enhanced mechanism can also be used with the other PEPSTprobes in FIGS. 6B, 6C, 6D, 6E, 6F and 6G.

Plasmon resonances arise with in a metallic nanoparticle from thecollective oscillation of free electrons driven by an incident opticalfield. The plasmonic response of nanoparticles have played a role in agrowing number of applications, including surface-enhanced Ramanscattering (SERS), chemical sensing, drug delivery, photo thermal cancertherapy, and new photonic devices.

In one embodiment of the invention, the plasmonic structures have ametallic layer over a dielectric core. In one embodiment of theinvention, these shells include spheroidal shells, since the plasmonresonances (both longitudinal and transverse modes) are influenced byboth shell thickness and aspect ratio. A number of researchers haveexamined the plasmonic response of the solid spheroidal particle intheir analysis of surface-enhanced Raman scattering although thespheroidal shell appears not to have been investigated. The inventionalso includes prolate and oblate spheroidal shells, which show someinteresting qualitative features in their plasmon resonances. Thespheroidal shell presents two degrees of freedom for tuning: the shellthickness and the shell aspect ratio [S. J Norton and T. Vo-Dinh,“Plasmonic Resonances of Nanoshells of Spheroidal Shape”, IEEE Trans.Nanotechnology, 6, 627-638 (2007)], the entire contents of which areincorporated herein by reference.

FIG. 7 shows some of the various embodiments of plasmonics-activenanostructures that can be designed, and are preferred embodiments ofthis invention:

(A) Metal nanoparticle;

(B) Dielectric nanoparticle core covered with metal nanocap;

(C) Spherical metal nanoshell covering dielectric spheroid core;

(D) Oblate metal nanoshell covering dielectric spheroid core;

(E) Metal nanoparticle core covered with dielectric nanoshell;

(F) Metal nanoshell with protective coating layer;

(G) Multi layer metal nanoshells covering dielectric spheroid core;

(H) Multi-nanoparticle structures;

(I) Metal nanocube and nanotriangle/nanoprism; and

(J) Metal cylinder.

In a further embodiment of the invention, the PA molecules can beincorporated in to a material (e.g., biocompatible polymer) that canform a nanocap on to the metal (gold) nanoparticles. The material can bea gel or biocompatible polymer that can have long-term continuousrelease properties. Suitable gel or biocompatible polymers include butare not limited to poly(esters) based on polylactide (PLA),polyglycolide (PGA), polycaprolactone (PCL), and their copolymers, aswell as poly(hydroxyalkanoate)s of the PHB-PHV class, additionalpoly(ester)s, natural polymers, particularly, modified poly(saccharide)s, e.g., starch, cellulose, and chitosan, polyethyleneoxides, poly(ether)(ester) block copolymers, and ethylene vinyl acetatecopolymers.

FIG. 8 shows other possible plasmonic embodiments of this invention withdielectric down-converting or up-converting material materials inproximity to metal shells or coating s. A plasmonics enhanced effect canoccur throughout the electromagnetic region provided suitablenanostructures, nanoscale dimensions, metal types are used.

In various embodiments of this invention, the metal nanoparticles arecovered with a layer (1-30 nm) of dielectric material (e.g. silica). Thedielectric layer (or nanoshell) is designed to prevent quenching of theluminescence light emitted by the energy modulation agent (also referredto as EEC) molecule(s) due to direct contact of the metal with theenergy modulation agent molecules. In yet other alternative embodiments,the energy modulation agent molecules or materials are bound to (or inproximity of) a metal nanoparticle via a spacer (linker). The spacer isdesigned to prevent quenching of the luminescence light emitted by theenergy modulation agent molecules or materials.

The energy modulation agent materials can include any materials that canabsorb X ray and emit light in order to excite the PA molecule. Theenergy modulation agent materials include, but are not limited to:

metals (gold, silver, etc);

quantum dots;

semiconductor materials;

scintillation and phosphor materials;

materials that exhibit X-ray excited luminescence (XEOL);

organic solids, metal complexes, inorganic solids crystals, rare earthmaterials (lanthanides), polymers, scintillators, phospho materials,etc.; and materials that exhibit excitonic properties.

Quantum dots, semiconductor nanostructures and various materials relatedto quantum dots, semiconductor materials, etc. can be used as energymodulation agents. Scintillator materials can be used as energymodulation agents. Various scintillator materials can be used as energymodulation agents since they absorb X-ray and emit luminescenceemission, which can be used to excite the PA system. For example, singlecrystals of molybdates can be excited by X-ray and emit luminescencearound 400 nm [Mirkhin et al, Nuclear Instrum. Meth. In Physics Res. A,486, 295 (2002, the entire contents of which are incorporated herein byreference]. For example CdS (or CsCl) exhibit luminescence when excitedby soft X-ray [Jaegle et al, J. Appl. Phys., 81, 2406, 1997, the entirecontents of which are incorporated herein by reference]. XEOL materialssuch as lanthanides or rare earth materials can be used as energymodulation agents.

In the invention, the experimental parameters including size, shape andmetal type of the nano structure can be selected based upon theexcitation radiation, the photoactivation radiation, and/or the emissionprocess from the energy modulation agent system.

Combination Emitter Stimulation

As noted above, the invention provides methods for producing a change ina medium or body after generation of radiation inside the medium. Inthis method, an initiation energy source provides an initiation energythat penetrates the medium and induces internal radiation to produce adesired effect in the medium. In one embodiment of this invention, theeffect produced occurs by photostimulation of a chemical reaction drivenby a combination of emitters (e.g., x-ray down-converters) where theemitted light from each of the emitters individually is nominally notexpected to drive the chemical reaction (e.g., a UV-driven reactionstimulated primarily by light emitted in a visible spectrum or aUV-driven reaction stimulated by down-converting phosphors havingrespective emissions not in the UV range but may exhibit UV emissionwhen combined.)

In a most preferred embodiment, the present inventors have found thatchemical reactions known in the art to be driven by UV radiation in the300 to 400 nm range can be stimulated from light emitted from energyconverters which are considered to nominally have no emission in the 300to 400 nm range. The exact mechanism of this stimulation is not known atthis time. There is optical data evidence showing that the combinationof visible emitters produces an emission in the UV range. In otherwords, the inventors have discovered that combination of visibleemitters yields more than the expected summation of the emission peaks.In some cases, new peaks are observed in the UV range. In other cases,prominent peaks in the visible range disappear.

The data in the following figures show this effect.

FIGS. 9-12 show respective x-ray induced optical emission spectra fromphosphors having their dominant emissions in the red, green, orange, andyellow parts of the visible spectrum, respectively. The phosphors wereobtained from the following sources. “Ruby Red” obtained from Voltarc,Masonlite & Kulka, Orange, CT, and referred to as “Neo Ruby”; “FlamingoRed” obtained from EGL Lighting, Berkeley Heights N.J. and referred toas “Flamingo”; “Green” obtained from EGL Lighting, Berkeley Heights,N.J. and referred to as “Tropic Green”; “Orange” obtained from Voltarc,Masonlite & Kulka, Orange, CT, and referred to as “Majestic Orange”;“Yellow” obtained from Voltarc, Masonlite & Kulka, Orange, CT, andreferred to as “Clear Bright Yellow.” The “BP” phosphors are shown indetail below:

Emission Spectrum X-Ray Absorption Density Phosphor Peak Emiss g/cc XcalMaterial Emission Eff Eff K-edge Specific Crystal Hygro- Code Color (nm)(%) (Z) (keV) Gravity Structure scopic BP1 CaWO4: Pb 425 N BP2 Y2SiO5:Ce 410 N BP3 YTaO4 337 10 59.8 67.42 7.5 Monolithic N BP3-C YTaO4 337 1059.8 67.42 7.5 Monolithic N BP4 BASF - 1 460 BP5 BASF-2 490 BP6 YTaO4:Nb (*) 410 11 59.8 67.42 7.5 Monolithic N BP6-C YTaO4: Nb (*) BP7-CLaOBr: Tm3+ 360, 460 14 49.3 38.92 6.3 Tetragonal N (coated) BP8-C LaF3:Ce 280 BP9 Y2O3 365 BP-10 BaSO4—: Eu2+ 390 6 45.5 37.38 4.5 Rhombic N(coated) BP10-C BaSO4—: Eu2+ 390 6 45.5 37.38 4.5 Rhombic N (coated)BP11 LaOCl: Tm BP12 Y2O2S: Tm BP13 BaSi2O5: Pb2+ 350 N SrB6O10: Pb 360 NCsI: Na (Coated) 338 Y Gd2O2S: Tm Blue to Y Green

The “BP” phosphors are available from PhosphorTech Corporation ofKennesaw, Ga. and from BASF Corporation.

In general, these phosphors show individually the emission of radiationat wavelengths other than the “primary” color. While these phosphorsshow little if any indication of emission in the 300 to 400 nm range,the results below show the “UV-activity” of these phosphors once x-rayactivated.

When a “photo-caged” luciferin is exposed to UV light in the 300 to 400nm range, its photocage breaks releasing d-luciferin. Sinced-luciferinemits visible light upon reaction with luciferase and appropriateco-factors, exposure of the released d-luciferin to a controlled amountof luciferase provides for visible light production where the amount ofvisible light produced will be indicative of the amount of d-luciferinuncaged, and evidence of UV activation.

FIG. 13 is a plot of the levels a plot of the levels of relative lightoutput for d-luciferin/luciferase reactions obtained over time forindividual types of phosphors (i.e., no mixtures) exciting a UV-lightseverable photocage containing d-luciferin. The data shows that somelight is output which may be due to nucleophilic hydrolysis (i.e.hydroxide ion mediated) of the photocage by the phosphor additions. Theplot shows that the level of light output peaks initially and thendecays over time.

FIG. 14 is a chart comparing peak levels of read-out light fromdifferent mixtures (red-green RG, red-yellow RY, green-yellow GYred-green-yellow RGY). The first data group to the left-most set shows acontrol with the phosphor combinations not being exposed to x-ray. PBSrepresents a phosphate buffered saline control for each of the sets. Thesecond data group to the right shows little change in the read-outlevels for the x-ray kVp energy/phosphor loading (milligrams)/x-raytime/x-ray source distance (cm) of 320/10/4/20. However, the third datagroup to the right and the fourth data group to the right showsignificant light out put when either the x-ray source distanceincreased or the phosphor loading increased). Of these phosphorcombinations, the red yellow RY phosphor combination showed the highestincrease.

FIG. 15 is plot of a number of different phosphor combinations tested at160 kVp/20 mA anode current/an aluminum filter in the x-ray beam/50 cmspacing conditions for a 1.8 minute x-ray exposure, except of thephosphor group with no exposure to x-ray radiation (the control setmarked “CTRL”). FIG. 15 shows that phosphor combinations which showedthe highest light output relative to the control were red-flamingo (RF)and green-flamingo (GF). Red-yellow (RY) and orange-yellow (OY) alsoshowed higher light outputs relative to the control.

FIG. 16 is a composite plot of x-ray induced optical emission spectra ofvarious individual visible emitting phosphors overlaid on each other.The “Gd₂O₂SEuX” phosphor is the strongest emitter. The “BaMgAlEuX”phosphor has peaks the closest to the UV range. (The “X” here refers toa dopant element present such as for example Tm.)

Yet, when combinations of these phosphors are used as x-ray induced downconversion to drive reactions known to be driven by UV wavelengths inthe 300 to 400 nm range, unexpectedly, photoreactions occur.

Optically, certain combinations of these phosphors showed more than thenormal expected results. FIG. 17A shows the x-ray induced opticalemission spectrum from a red-yellow (RY) phosphor combination. Ascompared to x-ray induced optical emission spectra of FIG. 12 (yellow;Y) and FIG. 9 (red; R), the spectrum of FIG. 17A showed a pronouncedreduction in the emission around 500 nm. There also appeared to be theonset of unexpected emissions (although small) in the 300-400 nmwavelength range. These observation seem consistent with the resultsshown for red-yellow RY in both FIGS. 14 and 15 where substantialUV-driven reactions for red-yellow RY were observed.

Meanwhile, FIG. 17B is a depiction of another x-ray induced opticalemission spectrum from a red-green RG phosphor combination, showing theonset of a feature around 290 nm. As compared to x-ray induced opticalemission spectra of FIG. 10 (green; G) and FIG. 9 (red; R), the spectrumof FIG. 17B shows no unexpected change and does not appear to show theonset of emissions in the 300-400 nm wavelength range. This observationseems consistent with the results shown for red-green RG in FIGS. 14 and15 where the measured results for UV-driven reactions with red-green RGwere not substantially different than the control experiments.

However, some phosphor combination such as red, yellow, green RYG show aprominent peak in the 280 to 300 nm range which may be contributing tothe psoralen activation. FIG. 17C is a depiction of an x-ray inducedoptical emission spectrum from a red-yellow-green RYG phosphorcombination showing a prominent peak in the 280 to 300 nm range forsolutions of red-yellow-green phosphors in acetone (1) and in hexane(2).

Medical Applications

Drug Activation

X-ray and other high energy radiation penetrate the human body. Upontheir penetration in to the body tissue, the energy modulation agents ofthis invention interact with the incident radiation to generate thesecondary light (visible and/or ultraviolet light) as described above.As noted above, the secondary light can activate photoreactive drugssuch as psoralen or other types of photoreactive drugs known to beactivated by a UV and/or visible light source.

For example, in one embodiment of the invention, a material such as theyttrium oxide (or other phosphors or mixtures of phosphors as describedabove) is introduced in to the body. Yttrium oxide as a host is known tobe a down converter from X-ray radiation. In this particular example,X-ray incident radiation on the yttrium oxide will produce UV lightwhich would in turn be used to activate drugs such as psoralen for thetreatment of cancer. In this manner, a target organ having insidepsoralen or other photoreactive drugs can be treated by irradiation withx-rays or other high energy sources, producing in turn visible and/orultraviolet light for activation of the photoreactive drug.

Accordingly, in various embodiments the present invention providesmethod for the treatment of cell proliferation disorders, in which aninitiation energy source (e.g., x-ray or other high energy source)provides an initiation energy that activates an activatablepharmaceutical agent to treat target cells with in the subject. In onepreferred embodiment, the initiation energy source is applied directlyto the energy modulations agents whose light emission in turn activatesthe activatable pharmaceutical agent, preferably in proximity to thetarget cells. In one preferred embodiment, the initiation energy sourceis applied directly to the activatable pharmaceutical agent, preferablyin proximity to the target cells.

Within the context of here, the phrase“applied indirectly” (or variantsof this phrase, such as “applying indirectly”, “indirectly applies”,“indirectly applied”, “indirectly applying”, etc.), when referring tothe application of the initiation energy, means the penetration by theinitiation energy in to the subject beneath the surface of the subjectand to the activatable pharmaceutical agent with in a subject.

Although not intending to be bound by any particular theory or beotherwise limited in any way, the following theoretical discussion ofscientific principles and definitions are provided to help the readergain an understanding and appreciation of the present invention.

As used herein, the term “subject” is not intended to be limited tohumans, but may also include animals, plants, or any suitable biologicalorganism.

As used herein, the phrase “cell proliferation disorder” refers to ancondition where the growth rate of a population of cells is less than orgreater than a desired rate under a given physiological state andconditions. Although, preferably, the proliferation rate that would beof interest for treatment purposes is faster than a desired rate, slowerthan desired rate conditions may also be treated by methods of thepresent invention. Exemplary cell proliferation disorders may include,but are not limited to, cancer, bacterial infection, immune rejectionresponse of organ transplant, solid tumors, viral infection, autoimmunedisorders (such as arthritis, lupus, inflammatory bowel disease,Sjogrens syndrome, multiple sclerosis) or a combination thereof, as wellas aplastic conditions wherein cell proliferation is low relative tohealthy cell s, such as aplastic anemia. Particularly preferred cellproliferation disorders for treatment using the present methods arecancer, staphylococcusaureus (particularly antibiotic resistant strainssuch as methicillin resistant staphylococcusaureus or MRSA), andautoimmune disorders.

As used herein, an “activatable pharmaceutical agent” (alternativelycalled a “photoactive agent” or PA) is an agent that normally exists inan inactive state in the absence of an activation signal. When the agentis activated by a matching activation signal under activatingconditions, it is capable of effecting the desired pharmacologicaleffect on a target cell (i.e. preferably a predetermined cellularchange).

A photoactive compound that achieves its pharmaceutical effect bybinding to certain cellular structure in its active state may requirephysical proximity to the target cellular structure when the activationsignal is delivered. For such activatable agents, delivery of theactivation signal under non-activating conditions will not result in thedesired pharmacologic effect. Some examples of activating conditions mayinclude, but are not limited to, temperature, pH, location, state of thecell, presence or absence of co-factors. Selection of an activatablepharmaceutical agent greatly depends on a number of factors such as thedesired cellular change, the desired form of activation, as well as thephysical and biochemical constraints that may apply.

When activated, the activatable pharmaceutical agent may effect cellularchanges that include, but are not limited to, apoptosis, redirection ofmetabolic pathways, up-regulation of certain genes, down-regulation ofcertain genes, secretion of cytokines, alteration of cytokine receptorresponses, production or modulation of reactive oxygen species orcombinations thereof.

The mechanisms by which an activatable pharmaceutical agent may achieveits desired effect are not particularly limited. Such mechanisms mayinclude direct action on a predetermined target as well as indirectactions via alterations to the biochemical pathways. A preferred directaction mechanism is by binding the agent to a critical cellularstructure such as nuclear DNA, mRNA, rRNA, ribosome, mitochondrial DNA,or any other functionally important structures. Indirect mechanisms mayinclude modulation of or releasing metabolites upon activation tointerfere with normal metabolic pathways, releasing chemical signals(e.g. agonists or antagonists) upon activation to alter the targetedcellular response, and other suitable biochemical or metabolicalterations.

In one preferred embodiment the activatable pharmaceutical agent iscapable of chemically binding to the DNA or mitochondria at atherapeutically effective amount. In this embodiment, the activatablepharmaceutical agent, preferably a photoactivatable agent, is exposed insitu to an activating energy emitted from an energy modulation agent(e.g., light emitted from a predominantly visible-light emittingphosphor or a mixture of such phosphors).

An activatable agent may be a small molecule; a biological molecule suchas a protein, a nucleic acid or lipid; a supramolecular assembly; ananoparticle; a nanostructure, or combinations thereof; or any othermolecular entity having a pharmaceutical activity once activated.

The activatable agent may be derived from a natural or synthetic origin.Any such molecular entity that may be activated by a suitable activationsignal source to effect a predetermined cellular change may beadvantageously employed in the present invention. Suitable photoactiveagents include, but are not limited to: psoralens and psoralenderivatives, pyrene cholesteryl oleate, acridine, porphyrin,fluorescein, rhodamine, 16-diazorcortisone, ethidium, transition metalcomplexes of bleomycin, transition metal complexes of deglycobleomycin,organoplatinum complexes, alloxazines such as 7,8-dimethyl-10-ribitylisoalloxazine (riboflavin), 7,8,10-trimethylisoalloxazine (lumiflavin),7,8-dimethylalloxazine (lumichrome), isoalloxazine-adenine dinucleotide(flavine adenine dinucleotide[FAD], alloxazine mononucleotide (alsoknown as flavin mononucleotide [FMN] and riboflavine-5-phosphate),vitamin Ks, vitamin L, their metabolites and precursors, andnaphthoquinones, naphthalenes, naphthols and their derivatives havingplanar molecular conformations, porphyrins, dyes such as neutral red,methylene blue, acridine, toluidines, flavine (acriflavinehydrochloride) and phenothiazine derivatives, coumarins, quinolones,quinones, and anthroquinones, aluminum (111) phthalocyaninetetrasulfonate, hematoporphyrin, and phthalocyanine, and compounds whichpreferentially adsorb to nucleic acids with little or no effect onproteins. The term“alloxazine” includes isoalloxazines.

Endogenously-based derivatives include synthetically derived analogs andhomologs of endogenous photo activated molecules, which may have or lacklower (1 to 5 carbons) alkyl or halogen substituents of thephotosensitizers from which they are derived, and which preserve thefunction and substantial non-toxicity. Endogenous molecules areinherently non-toxic and may not yield toxic photoproducts afterphotoradiation.

The nature of the predetermined cellular change will depend on thedesired pharmaceutical outcome. Exemplary cellular changes may include,but are not limited to, morphologic changes, apoptosis, necrosis,up-regulation of certain genes, down-regulation of certain genes,modulation of or secretion of cytokines, alteration of cytokine receptorresponses, or a combination thereof.

The energy modulation agent may be preferably directed to the desiredsite (e.g. a tumor) by systemic administration to a subject. Forexample, a light-emitting energy modulation agent may be concentrated inthe tumor site by physical insertion or by conjugating the lightemitting energy modulation agent with a tumor specific carrier, such asan antibody, nucleic acid, peptide, a lipid, chitin orchitin-derivative, a chelate, a surface cell receptor, molecularimprints, aptamers, or other functionalized carrier that is capable ofconcentrating the light-emitting source in a specific target tumor.

Although the activatable pharmaceutical agent and the energy modulationagent can be distinct and separate, it will be understood that the twoagents need not be independent and separate entities. In fact, the twoagents may be associated with each other via a number of differentconfigurations. Where the two agents are independent and separatelymovable from each other, they generally interact with each other viadiffusion and chance encounters with in a common surrounding medium.Where the activatable pharmaceutical agent and the energy modulationagent are not separate, they may be combined in to one single entity.

In a preferred embodiment, the photoactivatable agent, upon activation,binds to DNA or RNA or other structures in a cell. Other means forinteraction of the photoactivatable agent with the DNA or RNA arepossible, and this invention is not limited to any particular theory ofinteraction. Regardless, the activated energy state of thephotoactivatable agent is capable of causing damage to cells, inducingapoptosis. The mechanism of apoptosis is associated with an enhancedimmune response that reduces the growth rate of cell proliferationdisorders and may shrink solid tumors, depending on the state of thepatient's immune system, concentration of the agent in the tumor,sensitivity of the agent to stimulation, and length of stimulation.

A preferred method of treating a cell proliferation disorder of thepresent invention administers a photoactivatable agent to a patient,stimulates the photoactivatable agent to induce cell damage, andgenerates an auto vaccine effect.

Another advantage of using the visible phosphors and mixtures there ofis that side effects of UV induced damage can be greatly reduced bylimiting the production of free radicals, singlet oxygen, superoxide,hydroxyl radicals, thiyl radicals, hydrogen peroxide, and other highlyreactive groups that are known to damage healthy cells. Furthermore,additional additives such as antioxidants, may be used to further reduceundesired effects of irradiation.

Within the context of the present invention the administering of theinitiation energy source means the administration of an agent, thatitself produces the initiation energy, in a manner that permits theagent to arrive at the target cell with in the subject without beingsurgically inserted in to the subject. The administration can take anyform, including, but not limited to, oral, intravenous, intraperitoneal,inhalation, etc. Further, the initiation energy source in thisembodiment can be in any form, including but not limited to, tablet,powder, liquid solution, liquid suspension, liquid dispersion, gas orvapor, etc.

Psoralen Activation

Accordingly, combinations of more than two “visible” phosphors can beused in this invention. Discussed below are x-ray settings and massratios for clonogenic cell kill experiments. F1 refers to the insertionof an aluminum filter in to the x-ray beam to act as a filter.

xRT settings (kvp/mA) LDLE 20/20/F1, 30 seconds = 0.1 Gy LDHE 80/20/F1,30 seconds = 0.2 Gy HDHE 80/20/F1, 2.5 minutes = 1.0 Gy HDLE 20/20/F1,2.5 minutes = 0.5 Gy Mass ratio 1a Red/Yellow/Green (40/40/20) 1bRed/Yellow/Green (45/45/10) 2a Flamingo/Yellow/Green (40/40/20) 2bFlamingo/Yellow/Green (45/45/10)

Psoralen is known to be activated by UV light in the range from 300 to400 nm. Thus, a measure of cell kill would normally be assumed to beanindirect measure of the internal generation of UV light.

FIGS. 18A and 18B is a plotted cell kill comparison (shown here as thenumber of surviving colonies) between B16 cancer cells treated with andwith out psoralen (i.e., AMT) with different phosphor mixtures, butotherwise being x-ray stimulated and containing the multiple phosphorcombinations noted above. On these drawings, LDLE=low xRT dose lowenergy; HDHE=high xRT dose, high energy. Regardless of combination, thetreatment with psoralen in all cases shows an improved cell kill.

FIGS. 19A and 19B shows a similar comparison as in FIGS. 18A and 18B butat higher kVp x-ray conditions. On these drawings, LDLE=low xRT dose,low energy; HDHE=high xRT dose, high energy. Here, the comparisons ofresults between FIGS. 19A and 19B does not show an increased kill withpsoralen present.

FIG. 19C shows a clonogenic study utilizing a flamingo, yellow, greenFYG phosphor combination. These results with and with out Psoralen(i.e., the AMT) show a pronounced cell kill when the Psoralen ispresent.

Moreover, HPLC MS/MS analysis of synthetic (i.e. pdAdT) DNA samplesafter exposure to the x-ray activated multiple visible-light emittingphosphors of this invention showed the presence of mono-adducts ofpsoralen and in some cases psoralen cross-links with the DNA, consistentwith the photoactivation of psoralen The tables below show these resultsand the capability of energy modulation agents having a normalpredominant emission on one wavelength range producing changes in amedium expected to need activation from a different wavelength range.

Poly-dAdT Crosslinking Data Using “Visible” Phosphors

Sample X-Ray Mono- # Treatment Time 150 μL Diluent DNA Adduct Crosslink1 160 kvp, 4 min G + R PBS Poly 6.13E+03 — 20 mA dAdT 2 160 kvp, 4 minY + R PBS Poly 2.80E+03 — 20 mA dAdT 3 160 kvp, 4 min Y + R H2O Poly4.46E+03 1.61E+04 20 mA dAdT 4 160 kvp, 4 min G + R H2O Poly — — 20 mAdAdT

Poly-dAdT Crosslinking Data Using “Visible” Phosphors

Sample X-Ray Mono- # Treatment Time 100 μL Diluent DNA Adduct Crosslink1 160 kvp, 4 min R + G PBS Poly 1.85E+03 20 mA dAdT 2 160 kvp, 4 min R +O PBS Poly 1.78E+03 20 mA dAdT 3 160 kvp, 4 min F + G PBS Poly 8.75E+0220 mA dAdT 4 80 kvp, 4 min F + G H2O Poly 6.87E+02 20 mA dAdT

The results with mixtures of two or more of the phosphors show thecapacity for “visible emitting” phosphors of this invention to activateUV-sensitive compounds. This capability permits a wider range ofphosphor combinations to be used which otherwise would have beendismissed (under conventional practice) as being useless for anUV-activated process.

Photo-Cage Activation

As described above, the energy modulation agents of a preferredembodiment of this invention (upon activation) can produce visibleand/or ultraviolet light which (even for predominantly visible lightemission) can open photocages designed for UV severance.

This unique capability permits the use of phosphors such as the red Rphosphors or mixtures of the red-green RG, red-yellow RY, green yellowGY, etc to release a chemically active species from a photocage.Moreover, it is known in the art that excessive UV light exposure candegrade properties of the medium, such as UV degradation of the polymersor DNA “light poisoning.”

Photocages such as nitrophenyl compounds photolyze with near-UV lightcentered a 50 nm, which lies in the UVA range (315-400 nm). Unlike UVB(280-315 nm) and UVC (100-280 nm), UVA is not absorbed by DNAappreciably and therefore does not directly cause DNA damage.

A nitrophenyl compound as a photocage for Ca is shown below:

Depending on the intensity of the light source, duration of exposure andcell type, however, UVA light can damage DNA and other cellularcomponents indirectly via the formation of reactive oxygen species.Light toxicity can therefore be a serious limitation of these photocagecompounds.

Hence, this preferred embodiment of the present invention whichactivates nominally UV activated photocages with predominantly visiblelight emitters (or emitters normally expected to have predominantlyvisible emissions) offers advantages when the medium being treated isparticularly suspect to UV degradation.

Moreover, there already exist a number of metal photocages investigatedfor cancer treatment. Of these, cisplatin has been studied and known forits toxicity to both healthy and cancerous cells. Pt^(IV) complexes aremore inert to ligand substitution than their Pt counterparts, andtherefore must be reduced to their active Pt^(II) form by extracellularand/or intracellular agents prior to reaction with DNA.

Workers have reported that, if the rate of reduction of Pt^(IV) toPt^(II) can be increased at or around a tumor relative to normal tissue,then the effectiveness of the drug could be maximized. The [PtCl₂I₂(en)]complex photo reduces with visible light. While the photoproducts werenot characterized, the resulting complex was shown to bind DNA. However,the unphotolyzed complex was also able to bind DNA, and there was nodifference in cytotoxicity observed for cells kept in the dark ascompared to those exposed to light. Accordingly, other Pt photocageswere developed.

Cis, trans, cis-[Pt(N₃)₂(OH)₂(NH₃)₂] have been found to be stable in thepresence of glutathione, and photolyzes into a complex that binds DNAand 5′-GMP. In addition, the photolyzed complex inhibits the growth ofhuman bladder cancer cells as well as cisplatin-resistant cells, whilecells treated with the complex and kept in the dark showed very littlegrowth inhibition.

Accordingly, the present invention provides a mechanism by whichmixtures of predominantly visible light emitters (or emitters normallyexpected to have predominantly visible emissions) can photoactivate(photolyze) Cis,trans,cis-[Pt(N₃)₂(OH)₂(NH₃)₂] with out significantdegradation and destruction of near by healthy cells by high UV exposureor singlet oxygen generation.

Photobiomodulation

Photobiomodulation also known as low level laser therapy (LLLT), coldlaser therapy, and laser biostimulation, is an emerging medical andveterinary technique in which exposure to low-level laser light canstimulate or inhibit cellular function leading to beneficial clinicaleffects. The “best” combination of wavelength, intensity, duration andtreatment intervals complex and sometimes controversial with differentdiseases, injuries and dysfunctions needing different treatmentparameters and techniques.

Certain wavelengths of light at certain intensities (delivered by laser,LED or another monochromatic source) will, for example, aid tissueregeneration, resolve inflammation, relieve pain and boost the immunesystem. The exact mechanism is still being explored and debated but itis agreed that the mechanism is photochemical rather than heat-related.Observe biological and physiological effects include changes in cellmembrane permeability, and up-regulation and down-regulation ofadenosine triphosphate and nitric oxide.

All light-induced biological effects depend on the parameters of theirradiation (wavelength, dose, intensity, irradiation time, depth of atarget cell, and continuous wave or pulsed mode, pulse parameters).

U.S. Ser. Nos. 12/417,779 and 12/764,184 (the entire contents of whichare incorporated herein by reference) describe non-invasive systems andmethods for in-situ photobiomodulation. In these different approaches, acondition, disorder or disease in a subject is treated using aninitiation energy source to induce a predetermined change in a targetstructure in a subject in situ to treat the condition, disorder ordisease. The initiation energy sources in these applications generateinternal light inside the subject to treat the condition, disorder ordisease.

In this invention, the combination of energy modulation agents(luminescent particles or down converters, mixtures of down converters,upconverters, mixtures of up converters, and combinations there of asdescribed above for example the mixtures of red, yellow, green, and/orblue phosphors noted above) would be provided inside a subject to betreated, and then activated by x-ray or some other source whoseactivation would be normally expected to produce light in a wavelengthrange which would not produce a photobiomodulation effect, but now uponexposure to the activation energy source would produce aphotobiomodulation effect treating a condition, disorder or disease inthe subject and therefore producing a change.

Commercial Applications

In the following commercial applications of the invention describedhere, the energy modulation agents 3 (e.g., luminescing particles orphoton emitters) are provided and distributed in to a medium 4 fordeactivation or activation of agents in the medium to produce aphysical, chemical, or biological change in the medium. In oneembodiment, plasmonics agents as described above are added to themedium. The plasmonics agents can enhance both the applied initiationenergy such that the enhanced initiation energy activates the at leastone activatable agent which produces a change in the medium whenactivated and can enhance light converted by the energy modulationagents.

In a preferred embodiment, the energy modulation agents include downconverters (such as for example phosphors which can convert x-ray orother high energy photon or particle into visible light. These downconverters when used in combination can activate a variety ofUV-stimulated photoreactions as well as activate any visible lightactivated reactions.

Examples of luminescing particles (down converters) can include goldparticles (such as for example the nanoparticles of gold), BaFBr:Euparticles, CdSe particles, Y₂O₃:Eu³⁺ particles, and/or other knownstimulated luminescent materials such as for example ZnS: Mn²⁺; ZnS:Mn²⁺, Yb^(3′), Y₂O₃: Eu³⁺; BaFBr:Tb³⁺; and YF₃:Tb³⁺. More specificexamples of the downconverters include, but are not limited to:BaFCl:Eu²⁺, BaSO₄ ⁻:Eu²⁺, LaOBr:Tm³⁺, YTaO₄, YTaO₄:Nb (*), CaWO₄,LaOBr:Tb³⁺, Y₂O₂S:Tb³⁺, ZnS:Ag, (Zn,Cd)S:Ag, Gd₂O₂S:Tb³⁺, La₂O₂S:Tb³⁺.

The embedded table below shows a listing of normally UV-emittingphosphors and their respective known peak emissions. Combinations of oneor more of these phosphors with or without the “visible” phosphorsdescribed above can be used in this invention.

Emission Spectrum X-ray Absorption Peak Emiss Microstructure EmissionEff Eff K-edge Specific Crystal Hygro- # Phosphor (nm) (%) (Z) (keV)Gravity Structure scopic 1 BaFCl: Eu²⁺ 380 13 49.3 37.38 4.7 TetragonalN 2 BaSO₄—: Eu²⁺ 390 6 45.5 37.38 4.5 Rhombic N 3 LaOBr: Tm³⁺ 360, 46014 49.3 38.92 6.3 Tetragonal N 4 YTaO₄ 337 59.8 67.42 7.5 Monolithic N 5YTaO₄: Nb (*) 410 11 59.8 67.42 7.5 Monolithic N 6 CaWO₄ 420 5 61.869.48 6.1 Tetragonal N 7 LaOBr: Tb³⁺ 420 20 49.3 38.92 6.3 Tetragonal N8 Y₂O₂S: Tb³⁺ 420 18 34.9 17.04 4.9 Hexgonal N 9 ZnS: Ag 450 17 26.79.66 3.9 Hexgonal N 10 (Zn, Cd)S: Ag 530 19 38.4 9.66/26.7 4.8 HexgonalN 11 Gd₂O₂S: Tb³⁺ 545 13 59.5 50.22 7.3 Hexgonal N 12 La₂O₂S: Tb³⁺ 54512.5 52.6 38.92 6.5 Hexgonal N

In addition to the inorganic compounds described here for downconverters, organic compounds can be used to achieve the same purposedescribed in the current invention. Anthracene and anthracene basedcompounds can be used to achieve the objective of the invention (curingwith no line of sight and thermal energy).

Anthracene exhibits a blue (400-500 nm peak) fluorescence underultraviolet light. Furthermore, it was found that anthracene exhibitsfluorescence under X-Ray energy. Anthracene light output was measured tobe 40% to 50% of Nal(Tl).

Various plastic scintillators, plastic scintillator fibers and relatedmaterials are made of polyvinyltoluene or styrene and fluors. These andother formulations are commercially available, such as from Saint GobainCrystals, as BC-414, BC-420, BC-422, or BCF-10.

Peak Product Emission Phosphor Reference (nm) Organic BC-414 392 OrganicBC-420 391 Organic BC-422 370Other polymers are able to emit in the visible range and these include:

Peak # of Phosphor Product Emission Photons (Fiber Forms) Reference (nm)Per MeV Organic BCF-10 432 8000 Organic BC-420 435 8000 Organic BC-422492 8000

Furthermore, the organic compounds that can convert X-ray to UV energycan be grafted (?) interwoven in to synthetic polymer chains. Thesechains can be used as the base resin system for a cross-linkingadhesive; hence leading to the formation of a new set of X-rayactivatable resin systems.

A more extensive list of phosphors suitable for this invention isincluded below. Combinations of one or more of these phosphors with orwith out the “visible” phosphors described above can be used in thisinvention.

Emission Spectrum X-Ray Peak Emiss Absorption Phosphor Emission Eff EffK-edge Specific Crystal Hydro- Item # Color (nm) (%) (Z) (keV) GravityStructure scopic 24 Zn3(PO4)2: Ti+ 310 N 33 BaF2 310 Slightly 30 CsI 315N 23 Ca3(PO4)2: Ti+ 330 N 4 YTaO4 337 59.8 67.42 7.5 Monolithic N 38CsI: Na 338 Y 14 BaSi2O5: Pb2+ 350 N 27 Borosilcate 350 N 34 LaCl3(Ce)350 Y 16 SrB4O7F: Eu2+ 350 N 20 RbBr: Ti+ 360 ? 15 (Ba, Sr, 370 NMg)3Si2O7: Pb2+ 17 YAlO3: Ce3+ 370 N 37 BC-422 370 Organic ? 1 BaFCl:Eu2+ 380 13 49.3 37.38 4.7 Tetragonal N 2 BaSO4—: Eu2+ 350 6 45.5 37.384.5 Rhombic N 19 BaFBr: Eu2+ 390 ? 36 BC-420 391 Organic ? 35 BC-414 392Organic ? 25 SrMgP2O7: Eu2+ 394 N 18 BaBr2: Eu2+ 400 N 22 (Sr, 400 NBa)Al2Si2O8: Eu2+ 5 YTaO4: Nb (*) 410 11 59.8 67.42 7.5 Monolithic N 21Y2SiOS: Ce3+ 410 N 6 CaWO4 420 5 61.8 69.48 6.1 Tetragonal N 7 LaOBr:Tb3+ 420 20 49.3 38.92 6.3 Tetragonal N 8 Y2O2S: Tb3+ 420 18 34.9 17.044.9 Hexgonal N 13 Lu2SiO5: Ce3+ 420 N 26 Lu1.8Y0.2SiO5: Ce 420 N 9 ZnS:Ag 450 17 26.7 9.66 3.9 Hexgonal N 29 CdWO4 475 Slightly 28 Bi4Ge3O12(BGO) 480 N 10 (Zn, Cd)S: Ag 530 19 38.4 9.66/26.7 4.8 Hexgonal N 11Gd2O2S: Tb3+ 545 13 59.5 50.22 7.3 Hexgonal N 12 La2O2S: Tb3+ 545 12.552.6 38.92 6.5 Hexgonal N 31 Y3Al5O12 (Ce) 550 N 3 LaOBr: Tm3+ 360, 46014 49.3 38.92 6.3 Tetragonal N 32 CaF2(Eu) 435/300 N

Furthermore, the luminescing particles (downconverters, mixtures of downconverters, up converters, mixtures of up converters, and combinationsthereof) of the invention described here can be coated with insulatormaterials such as for example silica which will reduce the likelihood ofany chemical interaction between the luminescing particles and themedium. For biological applications of inorganic nanoparticles, one ofthe major limiting factors is their toxicity.

Generally speaking, all semiconductor nanoparticles are more or lesstoxic. For biomedical applications, nanoparticles with toxicity as lowas possible are desirable or else the nanoparticles have to remainseparated from the medium. Pure TiO₂, ZnO, and Fe₂O₃ are biocompatible.CdTe and CdSe are toxic, while ZnS, CaS, BaS, SrS and Y₂O₃ are lesstoxic. In addition, the toxicity of nanoparticles can result from theirinorganic stabilizers, such as TGA, or from dopants such as Eu²⁺, Cr³⁺or Nd³⁺. Other suitable energy modulation agents which would seem themost biocompatible are zinc sulfide, ZnS:Mn²⁺, ferric oxide, titaniumoxide, zinc oxide, zinc oxide containing small amounts of Al₂O₃ and AgInanoclusters encapsulated in zeolite. For non-medical applications,where toxicity may not be as critical a concern, the following materials(as well as those listed elsewhere) are considered suitable: lanthanumand gadolinium oxyhalides activated with thulium; Er³⁺ doped BaTiO₃nanoparticles, Yb³⁺ doped CsMnCl₃ and RbMnCl₃, BaFBr:Eu²⁺ nanoparticles,Cesium Iodine, Bismuth Germanate, Cadmium Tungstate, and CsBr doped withdivalent Eu.

In various embodiments of the invention, the following luminescentpolymers are also suitable as energy modulation agents: poly(phenyleneethynylene), poly(phenylene vinylene), poly(p-phenylene),poly(thiophene), poly(pyridylvinylene), poly(pyrrole), poly(acetylene),poly(vinyl carbazole), poly(fluorenes), and the like, as well ascopolymers and/or derivatives thereof.

While many of the energy modulation agents of the invention aredownconversion agents (i.e. where higher energy excitation produceslower energy emission), U.S. Pat. No. 7,008,559 (the entire contents ofwhich are incorporated herein by reference) describes the upconversionperformance of ZnS where excitation at 767 nm produces emission in thevisible range. The materials described in U.S. Pat. No. 7,008,559including the ZnS as well as Er³⁺ doped BaTiO₃ nanoparticles and Yb³⁺doped CsMnCl₃ are suitable in various embodiments of the invention.

Further, in various embodiments of the invention, up converters can beused in combination with the down converters (or mixtures of downconverters) or in combination with various up converters. Various upconverters suitable for this invention include CdTe, CdSe, ZnO, CdS,Y₂O₃, MgS, CaS, SrS and BaS. Such up conversion materials may be anysemiconductor and more specific ally, but not by way of limitation,sulfide, telluride, selenide, and oxide semiconductors and theirnanoparticles, such as Zn_(1-x)Mn_(x)S_(y), Zn_(1-x)Mn_(x)Se_(y),Zn_(1-x)Mn_(x)Te_(y), Cd_(1-x)MnS_(y), Cd_(1-x)Mn_(x)Se_(y),Cd_(1-x)Mn_(x)Te_(y), Pb_(1-x)Mn_(x)S_(y), Pb_(1-x)Mn_(x)Se_(y),Pb_(1-x)Mn_(x)Te_(y), Mg_(1-x)MnS_(y), Ca_(1-x)Mn_(x)S_(y),Ba_(1-x)Mn_(x)S_(y) and Sr_(1-x), etc. (wherein, 0<x≦1, and 0<y≦1).Complex compounds of the above-described semiconductors are alsocontemplated for use in the invention—e.g.(M_(1-z)N_(z))_(1-x)Mn_(x)A_(1-y)By (M=Zn, Cd, Pb, Ca, Ba, Sr, Mg; N=Zn,Cd, Pb, Ca, Ba, Sr, Mg; A=S, Se, Te, O; B=S, Se, Te, O; 0<x≦1, 0<y≦1,0<z≦1). Two examples of such complex compounds areZn_(0.4)Cd_(0.4)Mn_(0.2)S and Zn_(0.9)Mn_(0.1)S_(0.8)Se_(0.2).Additional conversion materials include insulating and nonconductingmaterials such as BaF₂, BaFBr, and BaTiO₃, to name but a few exemplarycompounds. Transition and rare earth ion co-doped semiconductorssuitable for the invention include sulfide, telluride, selenide andoxide semiconductors and their nanoparticles, such as ZnS; Mn; Er; ZnSe;Mn, Er; MgS; Mn, Er; CaS; Mn, Er; ZnS; Mn, Yb; ZnSe; Mn, Yb; MgS; Mn,Yb; CaS; Mn, Yb etc., and their complex compounds: (M_(1-z)N_(z))_(1-x)(Mn_(q)R_(1-q))_(x)A_(1-y)B_(y) (M=Zn, Cd, Pb, Ca, Ba, Sr, Mg; N=Zn, Cd,Pb, Ca, Ba, Sr, Mg; A=S, Se, Te, O; B=S, . . . 0<z≦1, o<q≦1).

Indeed, some nanoparticles such as ZnS:Tb³⁺, Er³⁺; ZnS:Tb³⁺; Y₂O₃:Tb³⁺;Y₂O₃:Tb³⁺, Er3⁺; ZnS:Mn²⁺; ZnS:Mn, Er³⁺ are known in the art to have twofunctions, capable of functioning for both down-conversion luminescenceand upconversion luminescence.

To reduce the toxicity or to make these nanoparticles bio-inert orbiocompatible, one embodiment of the invention described here coatsthese nanoparticles with silica. Silica is used as a coating material ina wide range of industrial colloid products from paints and magneticfluids to high-quality paper coating s. Further, silica is bothchemically and biologically inert and also is optically transparent.Other coating suitable for this invention include polymethylmethacrylate (PMMA) coating and an ethyl-cellulose coating.

In one embodiment of this invention, luminescing particles (downconverters, mixtures of down converters, up converters, mixtures of upconverters, and combinations thereof) in encapsulated structures couldbe placed in the vicinity of the medium. In one embodiment for theinvention described here, luminescing particles are coated on theinterior of quartz or glass tubes and sealed. In another embodiment,luminescing particles could be coated on the surface of spheres ortubes, and afterwards encapsulated with silica (or other suitablepassivation layer) using a vapor deposition or sputtering process orspin-on glass process of the solution process described above to makethe encapsulation structures which may be part of re-entrant structuresextending from walls of a container or which may be part of a fluidizedbed structure. In another embodiment, the plasmonics agents are fixed toan outer surface of the glass tubes. External light applied to the tubesand scattered to the outer surfaces is enhanced at the plasmonics agentspermitting more efficient treatment of the medium with out necessarilyhaving to use energy modulation agents.

Sterilization and Cold Pasteurization of Fluids

It is known that ultraviolet (UV) with a wavelength of 254 nm tends toinactivate most types of microorganisms. The invention described hereinprovide in one embodiment configuration where energy modulation agentscan be placed inside fixtures such as quartz or glass with in the fluidmedium (water, fruit juices, dairy products, etc) and irradiated withx-ray s (or other penetrating radiation) through for example a plasticor aluminum container to activate the energy modulation agents in thefluid medium with internally generated visible and/or ultraviolet light.As such, the expense and fragility of a conventional sterilizationreactor constructed from glass of other similar structure can beavoided.

While discussed with regard to water, fruit juices, dairy products, etc,any other medium to be sterilized including food products, medicalproducts and cosmetic products could be treated using the technique ofthe invention described herein.

Sterilization of Medical and Pharmaceutical Articles

Gamma irradiation has been used conventionally to sterilize medicalbottle caps and other medical, pharmaceutical, and cosmetic articlessuch as surgical disposables (e.g., surgical bandages, dressings, gaugepads, nappies, delivery kits, and etc.), metallic products (e.g.,surgical blades, implants, aluminum caps, containers, etc.), and plasticand rubber Items (e.g., petri-dish, centrifuge tube, blood collectionsets, scalp veinsets, shunt valves, rubber gloves, contraceptivedevices, gowns, wraps covers, sheets, etc.). The invention would beapplicable for the sterilization of any “interior” surfaces of these andother products.

In one embodiment of the invention described herein, luminescentparticles (or down converters, mixtures of down converters,upconverters, mixtures of up converters, and combinations thereof) wouldbe included in an adhesive layer when the seal material is applied tothe bottle cap. X-ray irradiation would then be capable of curing theadhesive (if for example the adhesive were a photosensitive adhesive asdiscussed below in greater detail) and would produce with in theadhesive medium visible and/or ultraviolet radiation for sterilizationor for the production of singlet oxygen or ozone for biologicalgermicide. Additionally, plasmonics agents can be included to enhancethe effect of the incident radiation or the internally generated(visible and/or ultraviolet) radiation.

While illustrated here with regard to medical bottlecaps, otheradhesively constructed devices could benefit from these procedures inwhich the adhesive medium is cured and/or sterilized during activationof energy modulation agents.

Sterilization of Blood Products

U.S. Pat. No. 6,087,141 (the entire contents of which are incorporatedherein by reference) describes an ultraviolet light actived psoralenprocess for sterilization of blood transfusion products. Here, thisinvention can be applied for the treatment of or the neutralization ofAIDS and HIV or other viral or pathogenic agents in blood transfusionproducts. In this embodiment, at least one photoactivatable agent isselected from psoralens, pyrene cholesteryl oleate, acridine, porphyrin,fluorescein, rhodamine, 16-diazorcortisone, ethidium, transition metalcomplexes of bleomycin, transition metal complexes of deglycobleomycinorganoplatinum complexes, alloxazines, vitamin Ks, vitamin L, vitaminmetabolites, vitamin precursors, naphthoquinones, naphthalenes,naphthols and derivatives thereof having planar molecular conformations,porphyrin porphyrins, dyes and phenothiazine derivatives, coumarins,quinolones, quinones, and anthroquinones. These photoactivatable agentsare introduced into the blood product (or a patient's blood stream). Apenetrating energy is applied to the blood product (or to the patient).The down converters, mixtures of down converters, up converters,mixtures of up converters, and combinations there of (either included inthe blood product) or in encapsulated structures generates secondarylight (visible and/or ultraviolet) which activates the photoactivatableagents in the blood products.

In a specific example, the photoactivatable agent is a psoralen, acoumarin, or a derivative thereof, and as discussed above, one cansterilize blood products in vivo (i.e., in a patient) or in a containerof the blood product (such as for example donated blood). The treatmentcan be applied to treat disorders such as for example a cancer cell, atumor cell, an autoimmune deficiency symptom virus, or a blood-bornegermicides treated by the psoralen, the coumarin, or the derivativethereof.

Low kVp Systems

PCT application PCT/US12/45930 (the entire contents of which areincorporated herein by reference) describes a system for lightstimulation with in a medium. The system in the '930 application has areduced-voltage x-ray source configured to generate x-rays from a peakapplied cathode voltage at or below 105 kVp, and a first plurality ofenergy-emitting particles in the medium which, upon radiation from thex-ray source, radiate ala first lower energy than the x-ray source tointeract with the medium or with at least one photoactivatable agent inthe medium.

The x-ray induced emissions noted above represent merely one example ofa class where stimulated emission from a combination of energymodulation agents yields unexpected frequencies of emitted light. In oneembodiment of this invention, the above-noted energy modulation agents(and combinations thereof) can be used in low kVp systems to activatepsoralen and its derivatives.

Additionally, certain phosphors/phospho combinations may have differentexcitation optima for emission. Furthermore, certain phosphors/phosphorcombinations may have show increased emissions or an increased effectwhen the x-ray energy (kVp) of the beam is lowered.

Sterilization Methods and System Components

Optical techniques have been often used in sterilization procedures torender unwanted or harmful waterborne microorganisms incapable ofreproducing using ultraviolet light (specific ally the spectral area ofUV-C, 200 to 280 nm range). Ultraviolet light in the UV-C is consideredthe most lethal range as a germicidal disinfectant (capable of alteringa living microorganism's DNA, and keeping the microorganism fromreproducing). UV-C, with 264 nanometers being the peak germicidalwavelength, is known as the germicidal spectrum. Although the UV-Cmethod is simple and effective, it is not particularly effective insamples (gas, liquids, particulates) enclosed on containers which do nottransmit UV light. The present invention provides techniques and systemsthat can use externally applied radiation such as X-ray forsterilization. While illustrated below with respect to X-rayirradiation, and as discussed above, other suitable forms of energycould be used provided the containers and medium to be sterilized wassufficiently transparent for the medium to be thoroughly irradiated.Examples of alternative sources and materials for upconvertingluminescence to higher energies have been discussed above.

FIGS. 20-22 show various embodiments of sterilization systems and probesthat can be used with X ray excitation. More systems are described inU.S. Ser. No. 12/401,478 now U.S. Pat. No. 8,376,013, the entirecontents of which are incorporated herein by reference. These systemsare applicable in a number of the applications discussed above and iswell as in other sterilization areas. The systems could thus be used inthe waste water detoxification, blood sterilization, coldpasteurization, and photodeactivation commercial applications discussedin the sections above. These systems show the use of artificialcontainers in which the medium to be treated is disposed.

FIG. 20 shows one embodiment of a sterilization system of the inventionthat includes: a container and a material containing an X-ray energyconverter. The container holds a sample to be sterilized (e.g., liquid,gas, or particulates). X-ray radiation, capable of penetrating thecontainer wall, excites the material containing the X-ray excitationenergy converter (EEC), which is configured to emit emission light. TheEEC material is selected such that the emitted or luminescence lightoccurs in a spectral region that can be used for sterilization (e.g.,the ultraviolet spectral range).

FIG. 21 shows one embodiment of another sterilization system of theinvention that utilizes plasmonics and includes: a container, a materialcontaining an X-ray energy converter, a dielectric layer (e.g., silica),and a metal nanostructure (e.g., Au, Ag). The container holds a sampleto be sterilized (e.g., liquid, gas, or particulates). X-ray radiation,capable of penetrating the container wall, excites the materialcontaining the X-ray excitation energy converter (EEC), which in turnemits emission light. The EEC material is selected such that the emittedor luminescence light occurs in a spectral region that can be used forsterilization (e.g., an ultraviolet spectral range). The metalnanostructure is designed to amplify the luminescence light due to theplasmonics enhancement effect discussed above. The dielectric layer isdesigned to separate the material of the X-ray energy converter from themetal nanostructure in order to minimize or prevent possible quenchingof the luminescence. The optimal thickness of the dielectric layer isabout 1 to 5 nm such that the dielectric layer does not significantlyalter the plasmonics effect.

FIG. 22 shows an embodiment of a sterilization probe system of theinvention that includes a container which can hold the medium to besterilized and a probe made of material containing an X-ray energyconverter. The sample inside the container can be liquid, gas, orparticulates. X-ray radiation, capable of penetrating the containerwall, excites the probe having the material containing X-ray excitationenergy converter (EEC), which in turn emits emission light. The EECmaterial is selected such that the emitted or luminescence light occursin a spectral region that can be used for sterilization (e.g., theultraviolet spectral range). The probe can be removed and reinserted into the container and reused.

In general, with out limitation to the sterilization systems discussedabove, in one aspect of the invention, there is provided a system forproducing a change in a medium disposed in an artificial container. Thesystem includes a mechanism configured to provide to the medium 1) anactivatable agent and 2) at least one energy modulation agent, Theenergy modulation agent is configured to emit light in to the mediumupon interaction with an initiation energy. The system includes aninitiation energy source configured to apply the initiation energy tothe medium. The energy modulation agent has a normal predominantemission of radiation in a first wavelength range (WR1) outside of asecond wavelength range (WR2) known to produce the change, but underexposure to the applied initiation energy produce the change.

Waste Water Detoxification

Photocatalysis has also been used as tertiary treatment for waste waterto comply with the regulatory discharge limits and to oxidize persistentcompounds that have not been oxidized in the biological treatment.Photocatalysis has being applied to the elimination of severalpollutants (e.g., alkanes, alkenes, phenols, aromatics, pesticides) withgreat success. In many cases, total mineralization of the organiccompounds has been observed. Several photocatalysts, such as CdS, Fe₂O₃,ZnO, WO₃, and ZnS, have been studied, but the best results have beenachieved with TiO₂P₂₅. These photocatalyst are usable for the inventiondescribed here.

The waste waters of an oil refinery are the waters resulting fromwashing the equipment used in the process, undesirable wastes, andsanitary sewage. These effluents have high oil and grease contents,besides other organic compounds in solution. These pollutants form aresidual chemical oxygen demand (COD) that may pose serious toxichazards to the environment.

In the invention described herein, downconverters, mixtures of downconverters, up converters, mixtures of up converters, and combinationsthereof would be placed inside quartz or glass fixtures with in thewaste water or would be placed on silica encapsulated structures withinthe waste water which, like the photocatalytic TiO₂, could be entrainedin the waste water during the irradiation. Additionally, the plasmonicsagents can be included to enhance the effect of the incident radiationor the internally generated radiation.

Upon irradiation with x-rays (or other penetrating radiation) throughfor example a plastic or aluminum container, activation of theluminescing particles (down converters, mixtures of down converters, upconverters, mixtures of up converters, and combinations thereof)) wouldgenerate secondary light (visible and/or ultraviolet) in near bypresence of the photocatalytic agent. In other words for the inventiondescribed herein, the down converters, mixtures of down converters,upconverters, mixtures of up converters, and combinations thereof (i.e.,energy modulation agents) are mixed along with the photocatalyticsemiconductor particles in the wastewater fluid stream, and the exterioractivation energy source penetrates the container (e.g., a plastic oraluminum container) and irradiates the bulk of the waste water,producing visible and/or UV light throughout the waste water which inturn drives the photocatalytic reactions. In one embodiment, theplasmonics agent are complexed with the luminescent particles or otherenergy modulation agents prior to being added to the fluid stream.

As such, the invention described herein offers a number to advantagesover that described above, including the elimination of expensiveholding tanks for the waste water, the avoidance of having to pump thewaste water at higher pressures or flowrates to produce sufficientturbulence, and the generation of UV light throughout the wastewater tothere by provide faster bulk processing of the waste water.

Photostimulation

Photostimulation is a field in which light is applied to in order toalter or change a physical property. For example, there has been anincreased focus on the use of biodegradable polymers in consumer andbiomedical fields. Polylactic acid (PLA) plastics andpolyhydroxyalkanoates (PHA) plastics have been playing a vital role infulfilling the objectives. But their relatively hydrophobic surfaceslimit their use in various applications. Hence, there is a need tosurface modify these film surfaces. Due to the lack of any modifiableside chain groups, workers have used a sequential two step photograftingtechnique for the surface modification of these biopolymers. In stepone, benzophenone was photografted on the film surface and in step two,hydrophilic monomers like acrylic acid and acrylamide werephotopolymerized from the film surfaces.

UV irradiation is known to affect graft copolymerization. UV-assistedphotografting in ethanol has been used to grow hydrophilic polymers(e.g., poly(acrylic acid) and polyacrylamide) from the surfaces of PLA,PHA, and PLA/PHA blend films. In that work, a functional polyurethane(PU) surface was prepared by photo-grafting N, N-dimethylaminoethylmethacrylate (DMAEM) on to the membrane surface. Graftingcopolymerization was conducted by the combined use of thephoto-oxidation and irradiation grafting. PU membrane was photo-oxidizedto introduce the hydroperoxide groups on to the surface, then themembrane previously immersed in monomer solution was irradiated by UVlight. Results have shown prior to the invention that UV irradiation canrealize graft copolymerization effectively.

In the invention described herein, these processes are expedited by theinclusion of down converters, mixtures of down converters, upconverters,mixtures of up converters and combinations thereof (serving as energymodulation agents) in dispersion in the fluid medium being used forphotostimulation. Additionally, the plasmonics agents can be included toenhance the effect of the incident radiation or the internally generatedradiation. In one embodiment the plasmonics agents are complexed withthese energy modulation agents prior to being added to the fluid medium.

Upon irradiation with x-rays (or other penetrating radiation) throughfor example a plastic or aluminum container, activation of theluminescing particles (i.e., energy modulation agents) would generatevisible and/or UV light throughout the volume of the medium (eliminatingany shadowing effects) and permitting batch or bulk type processing tooccur in parallel throughout the container.

In other examples, the interior generation of light (visible and/orultraviolet) inside a bulk medium may serve to stimulate a chemical orbiological process either by interaction of the light (visible and/orultraviolet) with activatable agents in the medium or the indirectgeneration of heat which the invention described here by way ofdispersed energy modulation agents would provide a controlled anduniform way to heat a vat of material in a biological or chemicalprocess.

Photodeactivation

In many industrial processes, especially food and beverage industries,yeasts are used to produce changes in a medium such as the conversion ofsugars in the raw product. One particularly prominent example is in thewine industry. Stopping the wine from fermenting any further wouldpreserve the current level of sweetness. Likewise allowing the wine tocontinue fermenting further would only make the wine less sweet witheach passing day. Eventually the wine would become completely dry atwhich time the fermentation would stop on its own. This is becauseduring the fermentation process yeast turns the sugar in to alcohol.

Ultraviolet light is known to destroy yeast cultures, but has restrictedapplications due to the inability of UV light to penetrate throughoutthe fluid medium. While heat can be used to destroy the yeast activity,cooking of the product may be premature or may produce undesirablechanges in the consistency and taste. For liquid or fluid food products,the same techniques described above for liquid pasteurization could beused here. For non-liquid products, energy modulation agents (downconverters, mixtures of own converters, upconverters, mixtures of upconverters, and combinations thereof) with little and preferably notoxicity (e.g. Fe oxides or titanium oxides) could be added. Externalactivation would result in the generation of visible and/or ultravioletlight within the liquid. Here, the concentration of these additiveswould likely be limited by any unexpected changes in taste.

Photo activated Cross-Linking and Curing of Polymers

In another embodiment of this invention, a system for curing of aradiation-curable medium includes 1) a mechanism configured to supply anuncured radiation-curable medium including an activatable agent and atleast one energy modulation agent in to the uncured radiation-curablemedium and 2) an initiation energy source configured to apply aninitiation energy throughout a region including the uncuredradiation-curable medium. The energy modulation agent has a normalpredominant emission of radiation in a first wavelength range (WR1)outside of a second wavelength range (WR2) known to activate thephotoinitiator, but under exposure to the applied initiation energycures the medium.

In this application, energy modulation agent down converters, mixturesof down converters, upconverters, mixtures of up converters, andcombinations thereof) are provided and distributed into an uncuredpolymer based medium for the activation of photosensitive agents in themedium to promote cross-linking and curing of the polymer based medium.Additionally, the plasmonics agents can be included to enhance theeffect of the incident radiation or the internally generated radiation.The plasmonics agents can be complexed with the luminescent particles orother energy modulation agents prior to being added to the polymer.

As noted above, for adhesive and surface coating applications, lightactivated processing is limited due to the penetration depth of UV lightin to the processed medium. In light activated adhesive and surfacecoating processing, the primary limitation is that the material to becured must see the light—both in type (wavelength or spectraldistribution) and intensity. This limitation has meant that one mediumtypically has to transmit the appropriate light. In adhesive and surfacecoating applications, any “shaded” area will require a secondary curemechanism, increasing cure time over the non-shaded areas and furtherdelaying cure time due to the existent of a sealed skin through whichsubsequent curing must proceed.

Conventionally, moisture-curing mechanisms, heat-curing mechanisms, andphoto-initiated curing mechanisms are used to initiate cure, i.e.,cross-linking, of reactive compositions, such as reactive silicones,polymers, and adhesives. These mechanism are based on eithercondensation reactions, whereby moisture hydrolyzes certain groups, oraddition reactions that can be initiated by a form of energy, such aselectromagnetic radiation or heat.

The invention described herein can use any of the following lightactivated curing polymers as well as others known in the art to whichthe luminescing particles (or energy modulation agents) are added.

For example, one suitable light activated polymer compound includes UVcuring silicones having methacrylate functional groups. U.S. Pat. No.4,675,346 to Lin, the disclosure of which is here by expresslyincorporated herein by reference, is directed to UV curable siliconecompositions including at least 50% of a specific type of siliconeresin, at least 10% of a fumed silica filler and a photoinitiator, andcured compositions thereof. Other known UV curing silicone compositionssuitable for the invention include organopolysiloxane containing a(meth)acrylate functional group, a photosensitizer, and a solvent, whichcures to a hard film. Other known UV curing silicone compositionssuitable for the invention include compositions of an organopolysiloxanehaving in average of at least one acryloxy and/or methacryloxy group permolecule; a low molecular weight polyacrylyl crosslinking agent; and aphotosensitizer.

Loctite Corporation has designed and developed UV and UV/moisture dualcurable silicone compositions, which also demonstrate high resistance toflammability and combustibility, where the flame-retardant component isa combination of hydrated alumina and a member selected from the groupconsisting of organo ligand complexes of transition metals,organosiloxane ligand complexes of transition metals, and combinationsthereof. See U.S. Pat. Nos. 6,281,261 and 6,323,253 to Bennington. Theseformulations are also suitable for the invention.

Other known UV photoactivatable silicones include siliconesfunctionalized with for example carboxylate, maleate, cinnamate andcombinations thereof. These formulations are also suitable for theinvention. Other known UV photoactivatable silicones suitable for theinvention include benzoin ethers (“UV free radical generator”) and afree-radical polymerizable functional silicone polymers, as described inU.S. Pat. No. 6,051,625 whose content is incorporated herein byreference in its entirety. The UV free radical generator (i.e., thebenzoin ether) is contained at from 0.001 to 10 wt % based on the totalweight of the curable composition. Free radicals produced by irradiatingthe composition function as initiators of the polymerization reaction,and the free radical generator can be added in a catalytic quantityrelative to the polymerizable functionality in the subject composition.Further included in these silicone resins can be silicon-bonded divalentoxygen atom compounds which can form a siloxane bond while the remainingoxygen in each case can be bonded to another silicon to form a siloxanebond, or can be bonded to methyl or ethyl to form an alkoxy group, orcan be bonded to hydrogen to form silanol. Such compounds can includetrimethylsilyl, dimethylsilyl, phenyldimethylsilyl, vinyldimethylsilyl,trifluoropropyldimethylsilyl, (4-vinylphenyl)dimethylsilyl,(vinylbenzyl)dimethyl silyl, and (vinylphenethyl)dimethyl silyl.

The photoinitiator component of the invention is not limited to thosefree radical generators given above, but may be any photoinitiator knownin the art, including the afore-mentioned benzoin and substitutedbenzoins (such as alkyl ester substituted benzoins), Michler's ketone,dialkoxyacetophenones, such as diethoxyacetophenone (“DEAP”)benzophenoneand substituted benzophenones, acetophenone and substitutedacetophenones and xanthone and substituted xanthones. Other desirablephotoinitiators include DEAP, benzoin methyl ether, benzoin ethyl ether,benzoin isopropyl ether, diethoxyxanthone, chloro-thio-xanthone,azobisisobutyronitrile, N-methyl diethanolamine benzophenone andmixtures thereof. Visible light initiators include camphoquinone,peroxyester initiator and non-fluorene-carboxylic acid peroxyesters.

Commercially available examples of photoinitiator suitable for theinvention include those from Vantico, Inc., Brewster, N.Y. under theIRGACURE and DAROCUR tradenames, specific ally IRGACURE184(1-hydroxycyclohexylphenyl ketone), 907(2-methyl-1-[4-(methylthio)phenyl]-2-morpholinopropan-1-one), 369(2-benzyl-2-N, N-dimethylamino-1-(4-morpholinophenyl)-1-butanone), 500(the combination of 1-hydroxy cyclohexyl phenylketone and benzophenone),651 (2,2-dimethoxy-2-phenyl acetophenone), 1700 (the combination ofbis(2,6-dimethoxybenzoyl-2,4,4-trimethyl pentyl) phosphine oxide andhydroxy-2-methyl-1-phenyl-propan-1-one), and 819[bis(2,4,6-trimethylbenzoyl)phenylphosphine oxide] and DAROCUR 1173(2-hydroxy-2-methyl-1-phenyl-1-propane) and 4265 (the combination of2,4,6-trimethylbenzoyldiphenyl-phosphine oxide and2-hydroxy-2-methyl-1-phenyl-propan-1-one); and IRGACURE 784DC(bis(.eta.sup.5-2,4-cyclopentadien-1-yl)-bis[2,6-difluoro-3-(1H-pyrrol-1-yl)phenyl]titanium).

Generally, the amount of photoinitiator (or free radical generators)should be in the range of about 0.1% to about 10% by weight, such asabout 2 to about 6% by weight. The free radical generator concentrationfor benzoin ether is generally from 0.01 to 5% based on the total weightof the curable composition.

A moisture cure catalyst can also be included in an amount effective tocure the composition. For example, from about 0.1 to about 5% by weight,such as about 0.25 to about 2.5% by weight, of the moisture curecatalyst can be used in the invention to facilitate the cure processbeyond that of photo-activated curing. Examples of such catalystsinclude organic compounds of titanium, tin, zirconium and combinationsthereof. Tetraisopropoxytitanate and tetrabutoxytitanate are suitable asmoisture cure catalyst. See also U.S. Pat. No. 4,111,890, the disclosureof which is expressly incorporated herein by reference.

It will be appreciated that the most efficient curing system will be onein which the particular photo-initiator is selected based on itsabsorption, its photo-catalysis sensitivity to the intensity of theincident radiation (i.e.; the efficiency of energy transfer).

Included in the conventional silicone composition (and other inorganicand organic adhesive polymers) suitable for the invention are variousinorganic fillers. For example, hollow microspheres supplied by Kishunder the trade name Q-CEL are free flowing powders, white in color.Generally, these borosilicate hollow microsphere are promoted asextenders in reactive resin systems, ordinarily to replace heavyfillers, such as calcium carbonate, there by lowering the weight ofcomposite materials formed therewith. Q-CEL5019 hollow microspheres areconstructed of a borosilicate, with a liquid displacement density of0.19 g/cm², a mean particle size of 70 microns, and a particle sizerange of 10-150 um. Other Q-CEL products are shown below in tabularform. Another commercially available hollow glass microsphere is sold byKish under the trade name SPHERICEL. SPHEREICEL 110P8 has a meanparticle size of about 11.7 microns, and a crush strength of greaterthan 10,000 psi. Yet other commercially available hollow glassmicrosphere are sold by the Schundler Company, Metuchen, N.J. under thePERLITE tradename, Whitehouse Scientific Ltd., Chester, UK and BM,Minneapolis, Minn. under the SCOTCHLITE tradename.

In general, these inorganic filler components (and others such as fumedsilica) add structural properties to the cured composition, as well asconfers flowability properties to the composition in the uncured stateand increase the transmissivity for the UV cure radiation. When present,the fumed silica can be used at a level of up to about 50 weightpercent, with a range of about 4 to at least about 10 weight percent,being desirable. While the precise level of silica may vary depending onthe characteristics of the particular silica and the desired propertiesof the composition and the reaction product thereof, care should beexercised by those persons of ordinary skill in the art to allow for anappropriate level of transmissivity of the inventive compositions topermit a UV cure to occur.

Desirable hydrophobic silicas include hexamethyldisilazane-treatedsilicas, such as those commercially available from Wacker-Chemie,Adrian, Mich. under the trade designation HDK-2000. Others includepolydimethylsiloxane-treated silicas, such as those commerciallyavailable from Cabot Corporation under the trade designation CAB-O-SILN70-TS, or Degussa Corporation under the trade designation AEROSILR202.Still other silicas include trialkoxyalkyl silane-treated silicas, suchas the trimethoxyoctyl silane-treated silica commercially available fromDegussa under the trade designation AEROSILR805; and 3-dimethyldichlorosilane-treated silicas commercially available from Degussa underthe trade designation R972, R974 and R976.

While these inorganic fillers have extended the use of conventional UVcured silicone systems to permit the curing of materials beyond a skindepth of UV penetration, these inorganic fillers alone do not overcomeshadowing effects and suffer from UV scattering which effectively makesfor a smaller penetration depth. In the invention described herein, theinclusion of these inorganic fillers along with luminescing particlesprovide a mechanism by which uniform light activated cures can occurdeep inside of the body of adhesive-solidified assemblies in regionsthat would normally be shadowed or not with the reach of external UV orother light sources.

Accordingly, conventional silicone and polymeric adhesive or release orcoating compositions are prepared using conventional mixing, heating andincubation techniques. Included in these conventional compositions areluminescing articles. These luminescing particle containing compositionscan then be applied to surfaces of objects to be fixed together or tosurfaces where a hard coating is desired or cast in a curable form forthe production of molded objects. The luminescing particles in thesecompositions upon activation will produce radiant light for photoactivated cure of the luminescing particle containing polymercomposition. The density of luminescing particles in these compositionswill depend on the “light transparency” of the luminescing particlecontaining composition. Where these compositions contain a significantamount of the inorganic filler as discussed above, the concentration ofluminescing articles can be reduced for example as compared to acomposition with a black color pigment where the light transparency willbe significantly reduced.

One advantage of the invention described here as seen from this exampleis that color pigments can be included in the light curable resinswithout significant compromise in the cured product performance. Thesecolor pigments may include one or more colored pigments well known tothose of ordinary skill in the art. Such pigments are generally metaloxides and include, but are not limited to, titanium dioxide, ironoxides, organic complexes, mica, talc and quartz. One pigment may beused, or a combination of two or more pigments may be utilized.Different colors can be obtained by choosing proper pigments andcombining them in a similar fashion as set forth in the followingexamples with the necessary adjustments common in the paint industry,being made. Accordingly, in one embodiment of the invention, these colorpigments including carbon black may also be included as an opticallyopaque materials to limit the propagation of internally generated lightfrom the point of generation.

U.S. Pat. No. 7,294,656 to Bach et al., the entire disclosure of whichis incorporated herein by reference, describes a non-aqueous compositioncurable by UV radiation broadly containing a mixture of two UV curableurethane acrylates that have several advantages over conventionalradiation-curable compositions. The Bache et al. compositions can becured in a relatively short time using UV-C (200-280 nm), UV-B (280-320nm),UV-A (320-400 nm) and visible (400 nm and above) radiation. Inparticular, Bache et al. compositions can be cured using radiationhaving a wavelength of 320 nm or more. When fully cured (regardless ofthe type of radiation used), the Bach et al. compositions exhibithardnesses and impact resistances at least comparable to conventionalcoatings.

In the invention described here, energy modulation agents (downconverters, mixtures of down converters, up converters, mixtures of upconverters, and combinations thereof) described above are added to theseBach et al. compositions, optionally including in one embodiment variouscolor pigments. Due to the fact that the exterior energy sourcepenetrates throughout the entirety of the Bach et al. compositions,thicker surface coating s can be realized. Further, the coating s can beapplied to intricate surfaces having for example been prepared withrecesses or protrusions. Curing with the recesses and around theprotrusions with out being limited by conventional UV shading willlikely provide enhanced adherence of the surface coating to the workpiece.

Moreover, in one embodiment of the invention an external energy sourceof the initiation energy can be directed to a structural element inwhich a gap (or crack) therein was filled with an uncuredradiation-curable medium (such as those described above). The internallygenerated light will cure or promote curing of the uncuredradiation-curable medium in the gap (or crack) there by providing arepair to the structure being irradiated.

Presently, there are available commercial epoxy systems which utilizeepoxy resin injection for the structural restoration of concrete. Epoxyinjection is very often the only alternative to complete replacement ofa structure. It therefore results in great cost savings. Besides fillingthe cracks, epoxy injection is known to protect rebar in the concreteand to stop water leakage. Commercially, the epoxy injection resinprovides a system for welding cracks which restores the originalstrength and loading originally designed in to the concrete. Typically,low viscosity resins are pressure injected in to the cracks. Often holesare drilled near or in to the cracks to provide a conduit for pumpingthe resin in to the cracks.

It, however, takes time for the resin to penetrate in to the thinner,even hair line cracks. Unfortunately, time is limited in the presentcommercial systems due to the fact that the resins are premixed withhardeners whose time to cure sets an upper limit for how long the lowviscosity resin can flow in to the cracks. Furthermore, time to completerepair is an issue in many industrial repairs as the hardener is usuallypresent in a concentration high enough to have the resin set for examplein twenty four (24) hours. Moreover, with traditional resin methods, itis not possible to induce curing at specific regions of interest sinceall the areas of the resin will be cured.

The present invention offers a number of advantages. Firstly the resinof the present invention will be a photoactivated resin which will notsubstantially cure until the x-ray source generates internal light(visible and/or ultraviolet) to activate the photoinitiators. Thisprovides more flexibility in pumping and waiting for complete crackfill. Secondly, once the photoactivatable resin is in place, its cure isthen activated, and the cure occurs at a rate not controlled by theconvention hardening reaction. Thirdly, the x-ray penetration throughthe concrete and the crack region will provide a more uniform mechanismfor cure of the resins, with the deep cracks being as likely to fullycure as the narrow cracks which may extend deeper into the material.Furthermore, the present invention allows the possibility to cure onlythe specific areas of interest, i.e., where the X-ray is irradiated.

In another embodiment of the present invention, the external energysource can be a directed or focused beam of the initiation energy whichcures an uncured radiation-curable medium to produce a patternedelement. In this embodiment, the structure holding or at least partiallyenclosing the uncured radiation-curable medium can be a structure opaqueto visible light. In this manner, the uncured radiation-curable medium(which normally would be photo activated upon exposure to ambient light)can be transported without premature curing. In this embodiment, thecuring would be activated for example by directed one or several focusedbeams of x-rays whose overlap generates regions in the structure holdingor at least partially enclosing the uncured radiation-curable mediumwhere the generated UV or visible light from the energy modulationagents in the medium would be of sufficient intensity to activate thephotoinitiators.

In this manner, precise three-dimensional and two-dimensional patterningcar be performed. In this manner, a number of differently sized anddifferent materials can be adhered to each other.

In general, in this aspect of this invention, a radiation-curable mediumcan be cured by applying an initiation energy throughout a compositioncomprising 1) an uncured radiation-curable medium and 2) at least oneenergy modulation agent. The initiation energy interacts with the energymodulation agent to directly or indirectly cure the uncured medium bypolymerization of polymers in the medium. The method includes curing theradiation-curable medium by activating a photoinitiator in theradiation-curable medium. The energy modulation agent has a normalpredominant emission of radiation in a first wavelength range (WR1)outside of a second wavelength range (WR2) known to activate thephotoinitiator, but underexposure to the applied initiation energy curesthe medium.

Thus, in one embodiment, the present invention provides aradiation-curable article including a radiation-curable medium and atleast one energy modulation agent distributed throughout the medium. Theenergy modulation agent being a substance which is capable of convertinginitiation energy to a light capable of curing the radiation-curablemedium by polymerization of polymers in the radiation-curable medium.The energy modulation agent has a normal predominant emission ofradiation in a first wavelength range (WR1) outside of a secondwavelength range (WR2) known to cure the radiation-curable medium, butunder exposure to the applied initiation energy cures theradiation-curable medium.

WORKING EXAMPLES

To demonstrate the present invention an adhesive chemistry was madeadding 75% by weight of PUMA 92-056 (from Rahn Corp) to 20% ofTriMethyl-Trimethylolpropane-Trimethacrylate (TMPTMA) from BASF and a 5%by weight of photo-initiator Darocur 1173 from BASF. The chemistry wasmixed with various phosphors (described below) ranging from 6% by weightto 20% by weight. The mixture was then stirred thoroughly and stored ina light-tight container.

There were three sets of phosphors evaluated. The first set of phosphorsincluded a 50%-50% mixture of the Flamingo-phosphor and theGreen-Phosphor. The second set of phosphors consisted of a 50%-50%mixture of the Red-phosphor and the Yellow-Phosphor. The third set ofphosphors consisted of a 25% of the Red-phosphor, 25% of theYello-phosphor, 25% of the Flamingo-phosphor, 25% of the Green-phosphor.

Furthermore, a fourth set of phosphors included a mixture of 50% ofLaOBr and 50% of YTaO4. The fourth set of phosphors were phosphors thatemit in the UV regime.

The adhesive/phosphor mixtures (about 0.2 grams) were placed between twoglass slides and cured under x-ray exposure. The x-ray energy was set at160 kVp and 20 mA and the distance from the X-Ray source was set at 10cm.

The adhesives loaded with the UV emitting phosphors cured in 2 minutesunder this x-ray setting. All of the other adhesives loaded 12.5% byweight with the three different set of phosphor combinations cured in2.5 minutes. The cured adhesive was qualitatively similar regardless ofthe “visible” or “ultraviolet” phosphors used.

Furthermore, a commercial adhesive system was modified by adding theappropriate amount of phosphor mixtures to ACU-TITE UV106G. Thisadhesive system contains by weight percent the following components:Acrylate oligomers 30-50%, Acryate esters 40-60%, Substituted acrylate1-10%, SILICA, AMORPHOUS, FUMED, 0.1-3%, Photoinitiators 1-5% andAdhesion promoter 0.1-1.5%. This adhesive was loaded with theFlamingo-Green phosphor mixture using 12.5% and cured in the x-ray. Thecure was under 1 min at 160 kVp, 20 mA when the sample was positioned ata distance of 1 cm.

The UV phosphors have a much higher light intensity output than the“visible” phosphors. Yet the “visible” phosphor mixture cures in aboutthe same amount of time and with approximately the same quality of cureas the UV phosphor-adhesive mixture. Controls with no phosphors of anykind showed no curing under x-ray exposure.

Patterned Element Curing

As an example in another embodiment, a patterned element such as adevice (such as plug to close a specific internal hole or path ways) canbe fabricated (e.g., cured) inside structures (e.g., building materials,man-made or natural underground storage tank, internal organs of humanbody, etc) using energy excitation (e.g., X ray) from the outside ofsuch structures. Another application of this technique would involve thefabrication of orthopedic structures inside the body, where the curableresin was introduced locally a the point of the orthopedic structure tobe formed and a directed or focused x-ray beam cured the structure.

Accordingly, in another embodiment of the present invention, there isprovided a method (and associated system) for producing a patternedelement inside a structure. The method places inside the structure aradiation curable medium including at least one of a plasmonics agentand an energy modulation agent (down converters, mixtures of downconverters, up converters, mixtures of up converters, and combinationsthereof). The energy modulation agent is configured to emit light in tothe medium upon interaction with an initiation energy. The methodapplies to the medium the initiation energy from a directed or focusedenergy source. The applied initiation energy interacts with theplasmonics agent or the energy modulation agent to generate light(visible and/or ultraviolet) at local regions inside the structure tocure locally the radiation curable medium.

As noted above, this method can form for the patterned element a plug toclose a hole or pathway in the structure such as for example holes orpathways in a building material, a man-made or natural undergroundstorage tank, or an internal organ in a human or animal body. The methodcan form for the patterned element a prosthetic device at a local pointin the body of a human or animal.

The method can further localize the curing by placing in the radiationcurable medium optically dense materials (such as the color pigmentsdiscussed above) to reduce propagation of the generated light from thepoint of generation.

Security and Product Tagging

In one embodiment of this invention, the x-ray induced emissions areused for security tags on wide variety of products including piracy tagsassociated with product identification. U.S. Pat. No. 8,389,958 (theentire contents of which are incorporated herein by reference) describein one embodiment, applications areas such as security and taggingoperations where a primary light source, for example a NIR beam isfocused and directed on to a target object. Applications of theabove-noted energy modulation agents described in this invention wouldpermit enhanced coding in areas such as for example: (i) detecting andremoving of counterfeit currency from circulation, (ii) detecting andremoving of counterfeit adulterated products (e.g., fake drugs), (iii)tracing the origin of products (e.g., alcohol, tobacco, firearms) andcommodities (e.g., oil/gas tag and trace), (iv) tagging controlledsubstances (e.g. military explosives) or restricted technology (e.g.nuclear and communications technologies)(v) marking single source, highvalue commodities (e.g., specialty fibers), and (vi) brand protection,and (vii) verifying the authenticity of documents, financial instruments(e.g. bearer bonds), and various forms of identification.

With UV incident on the above-noted energy modulation agents (andcombinations thereof), emissions in the visible wavelength range couldbe used as a first pass screening that the product identifier was inplace and for example to conclude that the product marking was proper.The UV illuminated mark could contain for example a passcode which theinspector would recognize.

Upon inspection, for example in a closed x-ray system, an x-ray beamincident on the above-noted energy modulation agents (and combinationsthereof) would produce x-ray induced emissions in the ultra-violet orvisible wavelength range which would then be detected and analyzed forauthentication. These inspection techniques would be similar to thosenoted in U.S. Pat. No. 8,389,958, except that here it would requireknowledge of the “secret” combination of energy modulation agents (e.g.,phosphors) to properly see a product-identifying wavelength or to read acharacteristic signature.

In conventional bar coding operations, a scanner is used to essentiallyread a series of black and white lines with the density and spacingsbeing indicative of a particular coded item. In this invention, theseprinted bar codes could make use of the energy modulation agents (andcombinations thereof) described above which offer the possibility of amulticolor emission from either x-ray (down-converting), ultraviolet(down-converting), or infrared (up-converting) sources.

Thus, the amount of information that can be encoded in to a traditionalbar code area may be greatly increased. For example, a specific colorcategorization could introduce completely different encodings for whatwould normally be the same series of black and white lines. Further,since many products are routinely inspected by x-ray analysis, thisinspection process with the tags of this invention using the above-notedenergy modulation agents (and combinations thereof) could in additionverify the manufacturer or packager for product tracking, safety, andmonitoring.

In these tagging and labeling applications, the invention provides asystem for identification of an object. The system includes a readablemedium (e.g., a paper product, a plastic product, and a glass productwhich may be a part of a security tag or a bar code on any product), aparticle acting as an energy modulation agent included in or on thesurface of the readable medium. The particle (i.e., the energymodulation agent) is configured to emit radiation in to the medium orbody upon interaction with an initiation energy. The energy modulationagent has a normal predominant emission of radiation in a firstwavelength range (WR1) outside of a second wavelength range (WR2). Inthis embodiment, information concerning the product is encoded in thesecond wavelength rang (WR2).

Color Enhancement

In one embodiment of this invention, the x-ray induced emissions notedabove represent merely one example of a class where stimulated emissionfrom a combination of energy modulation agents yields unexpectedfrequencies of emitted light (i.e., producing a changer enhancement inthe color of the medium). U.S. Ser. No. 13/204,355 (the entire contentsof which are incorporated herein by reference) describes systems forgenerating or enhancing light emission or reflectance from visibledisplays and colored surfaces so as to enhance the appearance of thevisible object. In the '355 application, a light emitting compositionincluded first color emitters configured to emit, upon exposure to anenergy source, visible light at a target color in response to absorptionof energy across a first band of wavelengths and including second coloremitters configured to emit, upon exposure to the energy source, visiblelight at the target color in response to absorption of energy across asecond band of wavelengths. The light intensity observable at the targetcolor was enhanced relative to reflected white light with out emissionfrom the first and second color emitters.

Here, with the above-noted energy modulation agents (and combinationsthereof), additional light enhancement would occur if the coloredsurfaces were exposed to an initiating radiation, such as x-rays (as inthe product security tagging application described above). However, theabove-noted energy modulation agents (and combinations thereof) do notin combination always produce the expected simple emission results.While not bound to any particular theory, it is possible that themechanism of emission, absorption, and re-emission changes theresultant“color” output. Thus, the combination of phosphors with theirnormally predominant emission at different distinctive wavelengths mayhave at least their relative strengths changed and altered (i.e.,changes in extent, intensity, spectral width, etc). For the human eye,the relative strengths are integrated.

Hence, a combination of the phosphors described above may well enhance aparticular color band relative to what color the eye would see for thecolored surface had the colored surface not have had included theabove-noted energy modulation agents (and combinations thereof). Thecombination of phosphors of this invention would be useful in paint,inks, displays, signs, pigments, cosmetics, fabrics, apparel, etc.

Solar Cell Conversion

As noted above, the x-ray induced emissions noted above represent merelyone example of a class where stimulated emission from a combination ofenergy modulation agents yields unexpected frequencies of emitted light.In one embodiment of this invention, the above-noted energy modulationagents (and combinations thereof) can be used to promote matching of thesolar spectrum to the spectral efficiency of a solar photoconversioncell, as described for example in U.S. Ser. No. 12/891,466 (the entirecontents of which are incorporated herein by reference). As explained inthe '466 application, photons with an energy below the band gap of theabsorber material cannot generate a hole-electron pair, and so theirenergy is not converted to useful output and only generates heat ifabsorbed. For photons with an energy above the band gap energy, only afraction of the energy above the band gap can be converted to usefuloutput. When a photon of greater energy is absorbed the excess energyabove the band gap is converted to kinetic energy of the carriercombination. The excess kinetic energy is converted to heat throughphonon interactions as the kinetic energy of the carriers slows toequilibrium velocity.

For a silicon solar cell assembly, the maximum sensitivity (because theenergy band structure of the monocrystalline silicon of 1.21 eV) is at awavelength of λ=950 nm. A monocrystalline silicon solar cell assembly isvirtually non-responsive to the ultraviolet (λ<400 nm).

The '466 application describes power conversion system includes a powerconversion device which produces electric power upon illumination andincludes a light conversion device which down-converts and up-converts aradiant source of energy in to a specific energy spectrum for theillumination of the power conversion device. The conversion elementincludes a first plurality of particles which upon radiation from afirst radiation source radiate at a higher energy than the firstradiation source, and includes a second plurality of particles whichupon radiation from the first radiation source radiate at a lower energythan the first radiation source.

Here, in this invention, the above-noted energy modulation agents (andcombinations thereof) would be used as the particles which uponradiation from the first radiation source radiate at a lower energy thanthe first radiation source. As noted above and while not bound to anyparticular theory, it is possible that the mechanism of emission,absorption, and re-emission within the above-noted energy modulationagents (and combinations thereof) change the resultant spectral output.Thus, the combinations with their normally predominant emission atdifferent distinctive wavelengths may have at least their relativestrengths changed and altered (i.e., changes in extent, intensity,spectral width, etc) and can be designed to match better the solarspectrum to the spectral efficiency of a solar photoconversion cell.

Computer-Assisted Control

In one embodiment of the invention, there is provided a computerimplemented system for designing and selecting suitable combinations ofinitiation energy source, energy modulation agent, and activatableagent. For example, the computer system 5 car include a centralprocessing unit (CPU) having a storage medium on which is provided: adatabase of excitable compounds, a first computation module for aphotoactivatable agent or energy transfer agent, and a secondcomputation module predicting the requisite energy flux needed tosufficiently activate the energy transfer agent or photoactivatableagent.

FIG. 4 illustrates a computer system 1201 for implementing variousembodiments of the invention. The computer system 1201 may be used asthe computer system 5 to perform any or all of the functions describedabove. The computer system 1201 includes a bus 1202 or othercommunication mechanism for communicating information, and a processor1203 coupled with the bus 1202 for processing the information. Thecomputer system 1201 also includes a main memory 1204, such as a randomaccess memory (RAM) or other dynamic storage device (e.g., dynamic RAM(DRAM), static RAM (SRAM), and synchronous DRAM (SDRAM)), coupled to thebus 1202 for storing information and instructions to be executed byprocessor 1203. In addition, the main memory 1204 may be used forstoring temporary variables or other intermediate information during theexecution of instructions by the processor 1203. The computer system1201 further includes a read only memory (ROM) 1205 or other staticstorage device (e.g., programmable read only memory (PROM), erasablePROM (EPROM), and electrically erasable PROM (EEPROM)) coupled to thebus 1202 for storing static information and instructions for theprocessor 1203.

The computer system 1201 also includes a disk controller 1206 coupled tothe bus 1202 to control one or more storage devices for storinginformation and instructions, such as a magnetic hard disk 1207, and aremovable media drive 1208 (e.g., floppy disk drive, read-only compactdisc drive, read/write compact disc drive, compact disc jukebox, tapedrive, and removable magneto-optical drive). The storage devices may beadded to the computer system 1201 using an appropriate device interface(e.g., small computer system interface (SCSI), integrated deviceelectronics (IDE), enhanced-IDE (E-IDE), direct memory access (DMA), orultra-DMA).

The computer system 1201 may also include special purpose logic devices(e.g., application specific integrated circuits (ASICs)) or configurablelogic devices (e.g., simple programmable logic devices (SPLDs), complexprogrammable logic device (CPLDs), and field programmable gate arrays(FPGAs)).

The computer system 1201 may also include a display controller 1209coupled to the bus 1202 to control a display, such as a cathode ray tube(CRT), for displaying information to a computer user. The computersystem includes input devices, such as a keyboard and a pointing device,for interacting with a computer user and providing information to theprocessor 1203. The pointing device, for example, may be a mouse, atrackball, or a pointing stick for communicating direction informationand command selections to the processor 1203 and for controlling cursormovement on the display. In addition, a printer may provide printedlistings of data stored and/or generated by the computer system 1201.

The computer system 1201 performs a portion or all of the processingsteps (or functions) of this invention in response to the processor 1203executing one or more sequences of one or more instructions contained ina memory, such as the main memory 1204. Such instructions may be read into the main memory 1204 from another computer readable medium, such as ahard disk 1207 or a removable media drive 1208. One or more processorsin a multi-processing arrangement may also be employed to execute thesequences of instructions contained in main memory 1204. In alternativeembodiments, hard-wired circuitry may be used in place of or incombination with software instructions. Thus, embodiments are notlimited to any specific combination of hardware circuitry and software.

As stated above, the computer system 1201 includes at least one computerreadable medium or memory for holding instructions programmed accordingto the teachings of the invention and for containing data structures,tables, records, or other data described herein. Examples of computerreadable media are compact discs, hard disks, floppy disks tape,magneto-optical disks, PROMs (EPROM, EEPROM, flash EPROM), DRAM, SRAM,SDRAM, or any other magnetic medium, compact discs (e.g., CD-ROM), orany other optical medium, punch cards, paper tape, or other physicalmedium with patterns of holes, a carrier wave (described below), or anyother medium from which a computer can read.

Stored on any one or on a combination of computer readable media, theinvention includes software for controlling the computer system 1201,for driving a device or devices for implementing the invention, and forenabling the computer system 1201 to interact with a human user. Suchsoftware may include, but is not limited to, device drivers, operatingsystems, development tools, and applications software. Such computerreadable media further includes the computer program product of theinvention for performing all or a portion (if processing is distributed)of the processing performed in implementing the invention.

The computer code devices of the invention may be any interpretable orexecutable code mechanism, including but not limited to scripts,interpretable programs, dynamic link libraries (DLLs), Java classes, andcomplete executable programs. Moreover, parts of the processing of theinvention may be distributed for better performance, reliability, and/orcost.

The term “computer readable medium” as used herein refers to any mediumthat participates in providing instructions to the processor 1203 forexecution. A computer readable medium may take many forms, including butnot limited to, non-volatile media, volatile media, and transmissionmedia. Non-volatile media includes, for example, optical, magneticdisks, and magneto-optical disks, such as the hard disk 1207 or theremovable media drive 1208. Volatile media includes dynamic memory, suchas the main memory 1204. Transmission media includes coaxial cables,copper wire and fiber optics, including the wires that make up the bus1202. Transmission media also may also take the form of acoustic orlight waves, such as those generated during radio wave and infrared datacommunications.

Various forms of computer readable media may be involved in carrying outone or more sequences of one or more instructions to processor 1203 forexecution. For example, the instructions may initially be carried on amagnetic disk of a remote computer. The remote computer can load theinstructions for implementing all or a portion of the invention remotelyin to a dynamic memory and send the instructions over a telephone lineusing a modem. A modem local to the computer system 1201 may receive thedata on the telephone line and use an infrared transmitter to convertthe data to an infrared signal. An infrared detector coupled to the bus1202 can receive the data carried in the infrared signal and place thedata on the bus 1202. The bus 1202 carries the data to the main memory1204, from which the processor 1203 retrieves and executes theinstructions. The instructions received by the main memory 1204 mayoptionally be stored on storage device 1207 or 1208 either before orafter execution by processor 1203.

The computer system 1201 also includes a communication interface 1213coupled to the bus 1202. The communication interface 1213 provides atwo-way data communication coupling to a network link 1214 that isconnected to, for example, a local area network (LAN) 1215, or toanother communications network 1216 such as the Internet. For example,the communication interface 1213 may be a network interface card toattach to any packet switched LAN. As another example, the communicationinterface 1213 may be an asymmetrical digital subscriber line (ADSL)card, an integrated services digital network (ISDN) card or a modem toprovide a data communication connection to a corresponding type ofcommunications line.

Wireless links may also be implemented. In any such implementation, thecommunication interface 1213 sends and receives electrical,electromagnetic or optical signals that carry digital data streamsrepresenting various types of information.

The network link 1214 typically provides data communication through oneor more networks to other data devices. For example, the network link1214 may provide a connection to another computer through a localnetwork 1215 (e.g., a LAN) or through equipment operated by a serviceprovider, which provides communication services through a communicationsnetwork 1216. The local network 1214 and the communications network 1216use, for example, electrical, electromagnetic, or optical signals thatcarry digital data streams, and the associated physical layer (e.g., CAT5 cable, coaxial cable, optical fiber etc). The signals through thevarious networks and the signals on the network link 1214 and throughthe communication interface 1213, which carry the digital data to andfrom the computer system 1201 may be implemented in baseband signals, orcarrier wave based signals. The baseband signals convey the digital dataas unmodulated electrical pulses that are descriptive of a stream ofdigital data bits, where the term “bits” is to be construed broadly tomean symbol, where each symbol conveys at least one or more informationbits. The digital data may also be used to modulate a carrier wave, suchas with amplitude, phase and/or frequency shift keyed signal that arepropagated over a conductive media, or transmitted as electromagneticwaves through a propagation medium. Thus, the digital data may be sentas unmodulated baseband data through a “wired” communication channeland/or sent with in a predetermined frequency band, different thanbaseband, by modulating a carrier wave. The computer system 1201 cantransmit and receive data, including program code, through thenetwork(s) 1215 and 1216, the network link 1214, and the communicationinterface 1213. Moreover, the network link 1214 may provide a connectionthrough a LAN 1215 to a mobile device 1217 such as a personal digitalassistant (PDA) laptop computer, or cellular telephone.

The re agents and chemicals useful for methods and systems of theinvention may be packaged in kits to facilitate application of theinvention. In one exemplary embodiment, a kit would comprise at leastone activatable agent capable of producing a predetermined cellularchange, at least one energy modulation agent capable of activating theat least one activatable agent when energized, optionally at least oneplasmonics agent that can enhance applied initiation energy such thatthe enhanced initiation energy activates the at least one activatableagent which produces a change in the medium when activated, andcontainers suitable for storing the various agents in stable form, andfurther comprising instructions for administering the at least oneactivatable agent and/or at least one energy modulation agent to amedium, and for applying an initiation energy from an initiation energysource to activate the activatable agent. The instructions could be inany desired form, including but non limited to, printed on a kit insert,printed on one or more containers, as well as electronically storedinstructions provided on an electronic storage medium, such as acomputer readable storage medium. Also optionally included is a softwarepackage on a computer readable storage medium that permits the user tointegrate the information and calculate a control dose, to calculate andcontrol intensity of the irradiation source.

System Implementation

In one embodiment of the invention, there is provided a first system forproducing a change in a medium (which may or may not to be disposed inan artificial container). The first system includes a mechanismconfigured to supply in the medium at least one of a plasmonics agentand an energy modulation agent (downconverters, mixtures of downconverters, up converters, mixtures of up converters, and combinationsthereof). The plasmonics agent enhances or modifies energy in a vicinityof itself. In one example, the plasmonics agent enhances or modifies theapplied initiation energy such that the enhanced initiation energyproduces directly or indirectly the change in the medium. The systemincludes an initiation energy source configured to apply an initiationenergy through the artificial container to the medium to activate the atleast one activatable agent in the medium.

In one embodiment, the applied initiation energy interacts with theenergy modulation agent to directly or indirectly produce the change inthe medium by emitted light (UV and/or visible light). The energymodulation agent predominantly emits light in a visible wavelength rangeto activate a normally ultraviolet activated photoreaction to producesaid change.

Viewed differently, the energy modulation agent has a normal predominantemission of radiation in a first wavelength range (WR1) outside of asecond wavelength range (WR2) known to produce a change. However, underexposure to the applied initiation energy the produces the changedirectly or indirectly.

In one embodiment, the normal predominant emission of the energymodulation agent is in the visible-light wavelength range, and thewavelength range WR2 is in the ultraviolet range. In one embodiment, thenormal predominant emission of the energy modulation agent ischaracterized by visible emissions in at least one of the red, yellow,green, blue, and not in the ultraviolet range. In one embodiment, theenergy modulation agent emits radiation in WR2. In one embodiment, theenergy modulation agent emits radiation in the ultraviolet range.

As used herein, “predominantly” means that the intensity of light in thevisible wavelength range (400 nm to 680 nm) is at least two to threetimes greater than light in the ultraviolet range (300 to 400 nm).

As used herein, “normal predominant emission” means the emission that anenergy modulation agent is normally expected to emit upon application ofan initiation energy. For example, the red, flamingo, yellow, green,blue phosphors noted above are normally expected to emit predominantlyin those wavelength ranges indicative of the name when activated forexample by UV light, x-ray, or electron beam. Other energy modulationagents for example upconverters might also be expected to normally emitpredominantly in the visible wavelength with no expected UV component.

In this invention, use of such energy modulation agents with a “normalpredominant emission” in a first wavelength range (WR1) outside of asecond wavelength range (WR2) known to produce a change in a medium,under exposure to appropriately selected initiation energy produceschanges in a medium or body normally expected to occur only with thesecond wavelength range WR2.

In one embodiment, the energy modulation agent converts the appliedinitiation energy and produces light (UV and/or visible light) at anenergy different from the applied initiation energy. The plasmonicsagent (if present) can enhance the light from the at least one energymodulation agent. In one embodiment, the applied initiation energysource is an external initiation energy source. In one embodiment, theapplied initiation energy source is a source that is at least partiallyin a container holding the medium.

The medium in one embodiment is substantially transparent to theinitiation energy. For example, if the medium is a liquid or fluid foodproduct such as orange juice which has a substantial amount of suspendedsolids, then UV light for example as described above and even visiblelight will be substantially absorbed and/or scattered by the orangejuice medium. Furthermore, microwave energy will likewise be absorbed bythis medium. However, an initiation energy source such as an X-raysource will essentially transmit entirely through for example an orangejuice medium. The effect is the medium can now be totally illuminatedwith the external initiation energy source.

Other sources and tuned to specific wavelengths may also be used as theinitiation energy source. These sources would take advantage of an“optical window” in the medium where for example a particular wavelengthof light would not be absorbed. Water selectively scatters and absorbscertain wavelengths of visible light. The long wavelengths of the lightspectrum—red, yellow, and orange—can penetrate to approximately 15, 30,and 50 meters (49, 98, and 164 feet), respectively, while the shortwavelengths of the light spectrum—violet, blue and green—can penetratefurther. Thus, for many aqueous based systems, non-high energy X-raysources may not be needed. In those situations energy modulation agentsand plasmonics agents would be added whose interaction with the emittedlight from the energy modulation agents (UV and/or visible light) wouldproduce for example photoactivation of catalysts in the aqueous medium.Light produced from the energy modulation agents can also be enhanced bythe plasmonics agents in the medium.

Accordingly, depending on the medium and the energy modulation agent andthe activatable agent, the initiation energy source can include at leastone of an X-ray source, a gamma ray source, and/or an electron beamsource. The initiation energy source can then be an energy sourceemitting a wavelength whose depth of penetration penetrates throughoutthe medium. The initiation energy in one embodiment may be scattered orabsorbed in the medium, but the plasmonics agents make useful theremnant light. The medium to be effected can be a medium to befermented, sterilized, or cold pasteurized. The medium to be effectedcan include bacteria, viruses, yeasts, and fungi.

The activatable agents can be photoactivatable agents such as thephotocages (described elsewhere) such that upon exposure to theinitiation energy source, the photocage disassociates rendering anactive agent available.

Indeed, as described above, photocages nominally considered breakableonly by UV-activated processes can be broken open by the down convertersmixtures of down converters, up converters, mixtures of up converters,and combinations thereof which normally would not be expected togenerate sufficient UV light for photocage breakage.

The activatable agents can include agents such as psoralens,pyrenecholesteryloleate, acridine, porphyrin, fluorescein, rhodamine,16-diazorcortisone, ethidium, transition metal complexes of bleomycin,transition metal complexes of deglycobleomycin organoplatinum complexes,alloxazines, vitamin Ks, vitamin L, vitamin metabolites, vitaminprecursors, naphthoquinones, naphthalenes, naphthols and derivativesthereof having planar molecular conformations, porphorinporphyrins, dyesand phenothiazine derivatives, coumarins, quinolones, quinones, andanthroquinones. The activatable agents can include photocatalysts suchas TiO₂, ZnO, CdS, CdSe, SnO₂, SrTiO₃, WO₃, Fe₂O₃, and Ta₂O₅ particles.

The first system can include a mechanism configured to provide in themedium energy modulation agents (down converters, mixtures of downconverters, upconverters, mixtures of up converters, and combinationsthereof) which converts the initiation energy to an activation energyfor activation of the activatable agent(s). Phosphorescent compounds,chemiluminescent compounds, and bioluminescent compounds can be includedin a photocage. The energy modulation agent(s) can be up conversion ordown conversion agents. The energy modulation agent(s) can beluminescent particles which emit light upon exposure to said initiationenergy. The luminescent particles can be nanoparticles of semiconductingor metallic materials. The luminescent particles can be chemiluminescentparticles which show enhanced chemiluminescence upon exposure tomicrowaves.

The first system can include a mechanism configured to provide in themedium plasmonics-agents including metal nanostructures such as forexample nanospheres, nanorods, nanocubes, nanopyramids, nanoshells,multi-layer nanoshell, and combinations thereof. The form and structureof these plasmonics-agents can vary as shown in the figure above.

Depending on the initiation energy source, the system can include acontainer for the medium that is permeable to the applied initiationenergy. For example, for an X-ray source, the container can be made ofaluminum, quartz, glass, or plastic. Furthermore, the container can be acontainer which receives and transmits the initiation energy to fluidproducts to pasteurize the fluid products, or can be a container whichreceives and transmits the initiation energy to fluid products toremediate contaminants in the fluid products.

In another embodiment of the invention, there is provided a secondsystem for curing a radiation-curable medium. The second system includesa mechanism configured to supply an uncured radiation-curable mediumincluding at least one plasmonics agent, energy modulation agents (downconverters, mixtures of down converters, up converters, mixtures of upconverters, and combinations thereof), and at least one activatableagent which produces a change in the radiation-curable medium whenactivated, and further includes an applied initiation energy sourceconfigured to apply initiation energy to a composition including theuncured radiation-curable medium, optionally the plasmonics agent, andthe energy modulation agent. The energy modulation agents as describedabove absorb the initiation energy and convert the initiation energy toan activation energy capable of curing the uncured medium (i.e.,promoting polymerization of polymers in the uncured medium). Theplasmonics agent enhances the applied initiation energy such that theenhanced initiation energy directly or indirectly cures the medium bypolymerization of polymers in the medium. For example, the plasmonicsagent an enhance the activation energy light such that enhanced lightactivates the at least one photoactivatable agent to polymerize polymersin the medium. In another example, activation of the energy modulationagent produces radiation (such as, for example, UV and/or visible light)which activates the at least one photoactivatable agent to polymerizepolymers in the medium.

The second system has attributes similar to the first system describedabove and can further permit the at least one activatable agent toinclude a photoinitiator such as one of benzoin, substituted benzoins,alkyl ester substituted benzoins, Michler's ketone,dialkoxyacetophenones, diethoxyacetophenone, benzophenone, substitutedbenzophenones, acetophenone, substituted acetophenones, xanthone,substituted xanthones, benzoin methyl ether, benzoin ethylether,benzoinisopropyl ether, diethoxyxanthone, chloro-thio-xanthone,azobisisobutyronitrile, N-methyl diethanolamine benzophenone,camphoquinone, peroxyester initiators, non-fluorene-carboxylic acidperoxyesters and mixtures thereof.

The second system can also include a mechanism configured to provide inthe medium plasmonics-agents including metal nanostructures such as forexample nanospheres, nanorods, nanocubes, nanopyramids, nanoshells,multi-layer nanoshell pd combinations thereof.

The second system can include a container for the uncuredradiation-curable medium that is permeable to the applied initiationenergy. The container can be configured to contain the uncuredradiation-curable medium or to hold a mold of the uncuredradiation-curable medium. The container as before can be an aluminumcontainer, a quartz container, a glass container, or a plasticcontainer, depending on the applied initiation energy.

In one embodiment, an energy source (e.g., an external energy source) isconfigured to irradiate the uncured radiation-curable medium in a jointregion (or regions) adhering one region of a utensil to another regionof the utensil. In another embodiment the energy source is configured toirradiate the joint regions and there by induce sterilization of thejoint regions due to the production of internal radiation (UV and/orvisible light) inside the joint regions. In another embodiment, theenergy source is configured to irradiate a surface coating. In anotherembodiment, the energy source is configured to irradiate a mold of theradiation-curable medium.

The radiation-curable medium in the surface coating or in the mold or inother medium can include color pigments to add color to a finished curedproduct. The radiation-curable medium in the surface coating or in themold or in another medium can include fumed silica to promote strengthand enhance distribution of the internally generated radiation (UVand/or visible light). The radiation-curable medium in the surfacecoating or in the mold or in another medium can include a moisture curepromoter to supplement the cure.

The second system provides one mechanism for production of novelradiation-cured articles, which include a radiation-cured medium,optionally at least one plasmonics agent, and at least one energymodulation agent distributed throughout the medium. The energymodulation agents (down converters, mixtures of down converters,upconverters, mixtures of up converters, and combinations thereof) beingsubstances which is capable of converting an applied energy to aradiation (UV and/or visible light) capable of producing a cure for theradiation-cured medium. The plasmonics agent enhances the appliedinitiation energy such that the enhanced initiation energy activates theenergy modulation agents.

Radiation produced from the energy modulation agent can also be enhancedby the plasmonics agents in the medium. The article can includeluminescent particles such as for example nanotubes, nanoparticles,chemilumiscent particles, and bioluminescent particles, and mixturesthereof. The article can include nanoparticles of semiconducting ormetallic materials. The article can include chemiluminescent particles.The article can include color pigments or fumed silica. The article caninclude plasmonics-agents including metal nanostructures such as forexample nanospheres, nanorods, nanocubes, nanopyramids, nanoshells,multi-layer nanoshells, and combinations thereof. The form and structureof these plasmonics-agents can include the probe structures detailedabove.

In another embodiment of the invention, there is provided a third systemfor producing a change in a medium disposed in an artificial container.The third system includes a mechanism configured to provide to themedium 1) an activatable agent and 2) at least one of a plasmonics agentand various energy modulation agents (downconverters, mixtures of downconverters, up converters, mixtures of up converters, and combinationsthereof). The energy modulation agent converts an initiation energy toan activation energy (UV and/or visible light) which then activates theat least one activatable agent. The third system further includes anapplied initiation energy source configured to apply the initiationenergy through the artificial container to activate the at least oneactivatable agent in the medium. The plasmonics agent enhances ormodifies an energy in a vicinity of itself. In one example, theplasmonics agent enhances or modifies the applied initiation energy suchthat the enhanced initiation energy produces directly or indirectly thechange in the medium.

The third system has similar attributes to the first and second systemsdescribed above, and further includes encapsulated structures includingat least one of the energy modulation agents and the plasmonics agents.The encapsulated structures can include nanoparticles of the energymodulation agents (down converters, mixtures of down converters, upconverters, mixtures of up converters, and combinations thereof)encapsulated with a passivation layer or can include sealed quartz orglass tubes having the energy modulation agent inside. The encapsulatedstructures can include sealed tubes having the plasmonics agent disposedon an outside of the sealed tube (which may or may not be exposeddirectly to the medium).

In another embodiment of the invention, there is provided a fourthsystem for producing a photo-stimulated change in a medium disposed inan artificial container. The fourth system includes a mechanismconfigured to provide in the medium at least one of a plasmonics agentand various energy modulation agents (down converters, mixtures of downconverters, up converters, mixtures of up converters, and combinationsthereof). The energy modulation agents convert an initiation energy toan activation energy (UV and/or visible light) which then produces thephoto-stimulated change. The fourth system further includes aninitiation energy source configured to apply the initiation energy tothe medium to activate the at least one energy modulation agent in themedium. The plasmonics agent enhances or modifies an energy in avicinity of itself. In one example, the plasmonics agent enhances ormodifies the applied initiation energy such that the enhanced initiationenergy produces directly or indirectly the change in the medium. Thesystem can include encapsulated structures including therein the energymodulation agents (down converters, mixtures of down converters, upconverters, mixtures of up converters, and combinations thereof). Theencapsulated structures can include nanoparticles of the energymodulation agent encapsulated with a passivation layer. The encapsulatedstructures can include sealed tubes having the plasmonics agent disposedon an outside of the sealed tube (which mayor may not be exposeddirectly to the medium).

The fourth system can include a container which receives and transmitsthe initiation energy to products with in the medium. The products caninclude plastics, where the activation energy alters the surfacestructure of the plastics. The products car include polylactic acid(PLA) plastics and polyhydroxyalkanoates (PHA) plastics. In thisembodiment, the activation energy can photo-graft a molecular species onto a surface of the plastics.

Having generally described this invention, a further understanding canbe obtained by reference to certain specific examples which are providedherein for purpose of illustration only and are not intended to belimiting unless otherwise specified.

Numerous modifications and variations of the invention are possible inlight of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practicedotherwise than as specifically described herein.

1. A method for producing a biological change in a medium or body,comprising: (1) placing in a vicinity of the medium or body one or morephosphors having a diamond-like carbon coating, said one or morephosphors configured to emit radiation into the medium or body uponinteraction with an initiation energy; and (2) applying the initiationenergy from an energy source to the medium or body, wherein the emittedradiation directly or indirectly produces the biological change in themedium or body.
 2. The method of claim 1, wherein said one or morephosphors includes at least one or more of CaWO₄:Pb²⁺, CaWO₄:W,Sr₃(PO₄)₂: Eu²⁺, Ba₃(PO₄)₂: Eu²⁺, Y₂SiO₅:Ce³⁺, SrMg(SiO₄)₂:Eu²⁺,BaMg₂Al₁₄O₂₄:Eu²⁺, ZnSiO₄::Mn²⁺, Y₃(Al,Ga)O₁₂:Ce³⁺, BaMg₂Al₁₄O₂₄:Mn²⁺,BaMgAl₁₄O₂₃:Mn²⁺, SrAl₁₂SiO₁₉:Mn²⁺, ZnAl₁₂O₁₉:Mn²⁺, CaAl₁₂O₁₉:Mn²⁺,YBO₃:Tb³⁺, Sr₄SiO₃Cl₄:Eu³⁺, Y₂O₃:Eu³⁺, Y₂SiO₅:Eu³⁺, Y₃Al₅O₁₂:Eu³⁺,CaSiO₃:Mn²⁺, YVO₄:Eu³⁺, Zn₂SiO₄:Mn²⁺.
 3. The method of claim 1, whereinsaid one or more phosphors includes at least one or more of silicates,phosphates, tungstates, and aluminates.
 4. The method of claim 4,wherein the one or more phosphors comprises one or more of visible-lightemitting phosphors and ultraviolet-light-emitting phosphors.
 5. Themethod of claim 1, wherein the one or more of phosphors comprises amixture of the phosphors.
 6. The method of claim 1, wherein applyingcomprises applying the initiation energy to activate a photoactivatableagent.
 7. The method of claim 6, wherein the photoactivatable agent isselected from psoralens, pyrene cholesteryloleate, acridine, porphyrin,fluorescein, rhodamine, 16-diazorcortisone, ethidium, transition metalcomplexes of bleomycin, transition metal complexes of deglycobleomycinorganoplatinum complexes, alloxazines, vitamin Ks, vitamin L, vitaminmetabolites, vitamin precursors, naphthoquinones, naphthalenes,naphthols and derivatives thereof having planar molecular conformations,porphorinporphyrins, dyes and phenothiazine derivatives, coumarins,quinolones, quinones, and anthroquinones.
 8. The method of claim 6,wherein the photoactivatable agent comprises a photocaged drug, apsoralen, a coumarin, or a derivative thereof.
 9. The method of claim 1,wherein the biological change produced is treatment of a cellproliferation disorder in a subject in need thereof.
 10. The method ofclaim 1, wherein applying comprises applying said initiation energy froma source emitting at least one of x-rays, gamma rays, and an electronbeam.
 11. The method of claim 1, wherein the one or more phosphorsfurther comprises a plasmonics agent including a metallic structure. 12.The method of claim 11, wherein the metallic structure comprises atleast one of nanospheres, nanorods, nanocubes, nanopyramids, nanoshells,multi-layer nanoshells, and combinations thereof.
 13. The method ofclaim 11, wherein the plasmonics agent comprises a dielectric-metalcomposite or a plurality of differently sized metal particles disposedin vicinity of each other as a composite plasmonics agent.
 14. Themethod of claim 1, wherein the biological change in the medium comprisesa change in organism activity.
 15. The method of claim 14, wherein thebiological change in activity comprises at least one of a sterilizationof the medium or a deactivation of fermentation in the medium.
 16. Themethod of claim 1, wherein applying comprises sterilizing said mediumincluding at least one organism selected from the group consisting ofbacteria, viruses, yeasts, and fungi.
 17. The method of claim 16,wherein applying comprises at least one of: sterilizing blood productsor food products; or pasteurizing the fluids or the food products. 18.The method of claim 1, wherein applying comprises applying theinitiation energy at a first dose level to cause an interim change andsubsequently applying the initiation energy at a second dose level tocause said biological change in the medium or body.
 19. The method ofclaim 1, wherein the diamond-like carbon coating is formed by a chemicalvapor deposition.
 20. The method of claim 19, wherein the diamond-likecarbon coating is formed by said chemical vapor deposition usinghydrogen gas and methane gas.